

10541677

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1612bxx

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	FEB 27	New STN AnaVist pricing effective March 1, 2006
NEWS	4	MAY 10	CA/Capplus enhanced with 1900-1906 U.S. patent records
NEWS	5	MAY 11	KOREAPAT updates resume
NEWS	6	MAY 19	Derwent World Patents Index to be reloaded and enhanced
NEWS	7	MAY 30	IPC 8 Rolled-up Core codes added to CA/Capplus and USPATFULL/USPAT2
NEWS	8	MAY 30	The F-Term thesaurus is now available in CA/Capplus
NEWS	9	JUN 02	The first reclassification of IPC codes now complete in INPADOC
NEWS	10	JUN 26	TULSA/TULSA2 reloaded and enhanced with new search and and display fields
NEWS	11	JUN 28	Price changes in full-text patent databases EPFULL and PCTFULL
NEWS	12	JUL 11	CHEMSAFE reloaded and enhanced
NEWS	13	JUL 14	FSTA enhanced with Japanese patents
NEWS	14	JUL 19	Coverage of Research Disclosure reinstated in DWPI
NEWS	15	AUG 09	INSPEC enhanced with 1898-1968 archive
NEWS	16	AUG 28	ADISCTI Reloaded and Enhanced
NEWS	17	AUG 30	CA(SM)/Capplus(SM) Austrian patent law changes
NEWS	18	SEP 11	CA/Capplus enhanced with more pre-1907 records
NEWS	19	SEP 21	CA/Capplus fields enhanced with simultaneous left and right truncation
NEWS	20	SEP 25	CA(SM)/Capplus(SM) display of CA Lexicon enhanced
NEWS	21	SEP 25	CAS REGISTRY(SM) no longer includes Concord 3D coordinates
NEWS	22	SEP 25	CAS REGISTRY(SM) updated with amino acid codes for pyrrolysine
NEWS	23	SEP 28	CEABA-VTB classification code fields reloaded with new classification scheme

NEWS EXPRESS JUNE 30 CURRENT WINDOWS VERSION IS V8.01b, CURRENT  
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),  
AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8
NEWS X25	X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific

Updated Search

10541677

research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 13:58:54 ON 16 OCT 2006

=> file hcaplus  
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

FILE 'HCAPLUS' ENTERED AT 13:59:25 ON 16 OCT 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 16 Oct 2006 VOL 145 ISS 17

FILE LAST UPDATED: 15 Oct 2006 (20061015/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s tanikawa, k?/au  
L1 346 TANIKAWA, K?/AU

=> s l1 and benzopyran  
12114 BENZOPYRAN  
1124 BENZOPYRANS  
12506 BENZOPYRAN  
(BENZOPYRAN OR BENZOPYRANS)  
L2 6 L1 AND BENZOPYRAN

=> d l2, ibib abs hitstr, 1-6

L2 ANSWER 1 OF 6 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:265407 HCAPLUS

DOCUMENT NUMBER: 134:295738

TITLE: Preparation of 4-oxybenzopyrans as antiarrhythmics

INVENTOR(S): Tanikawa, Keizo; Ohrai, Kazuhiko;  
Yanagihara, Kazufumi; Shigeta, Yukihiro; Tsukagoshi,  
Toru; Yamashita, Toru

PATENT ASSIGNEE(S): Nissan Chemical Industries, Ltd., Japan


SOURCE: PCT Int. Appl., 37 pp.  
CODEN: PIXXD2

Updated Search

10541677

DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001025224	A1	20010412	WO 2000-JP6877	20001003
W: AU, CA, CN, CZ, HU, IL, KR, LT, NO, NZ, RO, RU, SI, SK, UA, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 2000074539	A5	20010510	AU 2000-74539	20001003
JP 2001172275	A2	20010626	JP 2000-302996	20001003
EP 1218367	A1	20020703	EP 2000-963075	20001003
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO				
US 6677371	B1	20040113	US 2002-69002	20020329
PRIORITY APPLN. INFO.:			JP 1999-283861	A 19991005
			WO 2000-JP6877	W 20001003
OTHER SOURCE(S):		MARPAT 134:295738		
GI				



AB The title compds. [I; R1, R2 = H, alkyl, Ph; R3 = OH, alkylcarbonyloxy; R4 = H, cycloalkyl, alkyl, alkylcarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, aryl, heteroaryl; R5 = H, alkyl; X = absent, CO, SO2; R6 = H, alkyl, cycloalkyl; R7 = H, halo, NO2, CN] having the prolongation effect on the functional refractory period, and therefore are useful in treating arrhythmia (data given), were prepared and formulated. Thus, reacting 6-acetyl-amino-3,4-epoxy-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran with 2-phenethyl alc. in the presence of catalytic amount of concentrate H2SO4 in MeCN afforded 40% trans-I [R1, R2 = Me; R3 = OH; R4 = (CH2)2Ph; R5 = H; X = CO; R6 = Me; R7 = H].

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 2 OF 6 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:228880 HCAPLUS

DOCUMENT NUMBER: 134:237394

TITLE: Preparation and formulation of benzopyrans for pharmaceutical use as antiarrhythmic agents

INVENTOR(S): Tanikawa, Keizo; Ohrai, Kazuhiko; Yanagihara, Kazufumi; Shigeta, Yukihiro; Tsukagoshi, Toru; Yamashita, Toru

PATENT ASSIGNEE(S): Nissan Chemical Industries, Ltd., Japan

SOURCE: PCT Int. Appl., 67 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent



LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

Updated Search

## PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001021610	A1	20010329	WO 2000-JP6323	20000914
W: AU, CA, CN, CZ, HU, IL, KR, LT, NO, NZ, RO, RU, SI, SK, UA, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2383583	AA	20010329	CA 2000-2383583	20000914
AU 2000073143	A5	20010424	AU 2000-73143	20000914
AU 766935	B2	20031023		
JP 2001151767	A2	20010605	JP 2000-278994	20000914
EP 1212314	A1	20020612	EP 2000-961032	20000914
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, AL				
NZ 517404	A	20030131	NZ 2000-517404	20000914
RU 2234502	C2	20040820	RU 2002-110115	20000914
AT 311378	E	20051215	AT 2000-961032	20000914
NO 2002001294	A	20020315	NO 2002-1294	20020315
US 6589983	B1	20030708	US 2002-48026	20020329
HK 1047106	A1	20060428	HK 2002-108750	20021202
PRIORITY APPLN. INFO.:			JP 1999-264455	A 19990917
			WO 2000-JP6323	W 20000914
OTHER SOURCE(S):		MARPAT 134:237394		
GI				



AB Benzopyrans, such as I [R5 = aryl, heteroaryl; R8 = H, alkyl, cycloalkyl, etc.; X = CO, SO2; Y = bond or connecting group, with subunits such as (CH2)<sub>n</sub>, n = 0-4], were prepared and formulated for use as antiarrhythmics. Thus, benzopyran II was prepared in 61% yield by epoxide ring cleavage/amination of N-(1a,7b-dihydro-2,2-dimethyl-5-nitro-2H-oxireno[c][1]benzopyran-6-yl)acetamide with 2-phenethylamine using lithium perchlorate in THF. The prepared benzopyrans were tested for their effects on guinea pig left atrium muscle and right ventricular papillary muscle. Pharmaceutical formulations of the prepared benzopyrans were also presented.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 3 OF 6 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:228879 HCAPLUS

DOCUMENT NUMBER: 134:252263


TITLE: Preparation of 4-oxybenzopyran derivatives as antiarrhythmic agents

INVENTOR(S): Tanikawa, Keizo; Ohrai, Kazuhiko; Yanagihara, Kazufumi; Shigeta, Yukihiro; Tsukagoshi,

10541677

PATENT ASSIGNEE(S): Toru; Yamashita, Toru  
SOURCE: Nissan Chemical Industries, Ltd., Japan  
PCT Int. Appl., 45 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001021609	A1	20010329	WO 2000-JP6497	20000922
W: AU, CA, CN, CZ, HU, IL, KR, LT, NO, NZ, RO, RU, SI, SK, UA, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 2000073198	A5	20010424	AU 2000-73198	20000922
JP 2001158780	A2	20010612	JP 2000-287813	20000922
EP 1214307	A1	20020619	EP 2000-961181	20000922
EP 1214307	B1	20040407		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO				
US 6555574	B1	20030429	US 2002-49996	20020329
PRIORITY APPLN. INFO.:			JP 1999-269899	A 19990924
			WO 2000-JP6497	W 20000922
OTHER SOURCE(S):			MARPAT 134:252263	
GI				



AB 4-Oxybenzopyran derivs. I [R1, R2 = H, C1-6 alkyl, Ph; R3 = OH, C1-6 alkylcarbonyloxy; R4 = H, C3-6 cycloalkyl, C1-6 alkyl, C1-6 alkylcarbonyl, C1-6 alkylaminocarbonyl, di-C1-6 alkylaminocarbonyl, aryl, heteroaryl; n = 0-4; X = C(O)NR7, NR8, NHC(O)NH, S(O)2NH; R5 = H, hetaryl, etc.; R6 = H; halo, nitro, cyano] were prepared I are antiarrhythmic agents having prolongation effect on the functional refractory period. E.g., to (3R\*,4R\*)-3,4-epoxy-3,4-dihydro-2,2-dimethyl-6-(4-methoxyphenylacetyl-amino)-7-nitro-2H-1-benzopyran was added aqueous perchloric acid solution to give (3R\*,4S\*)-3,4-dihydro-2,2-dimethyl-6-(4-methoxyphenylacetyl-amino)-7-nitro-2H-1-benzopyran-3,4-diol.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 4 OF 6 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2000:707156 HCAPLUS

DOCUMENT NUMBER: 133:252312

TITLE: Preparation of chroman derivatives as antiarrhythmic drugs

INVENTOR(S): Tanikawa, Keizo; Ohrai, Kazuhiko; Yanagihara, Kazufumi; Shigeta, Yukihiro; Yamashita, Toru; Matsuda, Tomoyuki


PATENT ASSIGNEE(S): Nissan Chemical Industries, Ltd., Japan

Updated Search

10541677

SOURCE: PCT Int. Appl., 51 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000058300	A1	20001005	WO 2000-JP1364	20000307
W: AU, CA, CN, CZ, HU, IL, KR, LT, NO, NZ, RO, RU, SI, SK, UA, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
JP 2000336085	A2	20001205	JP 2000-79188	20000322
PRIORITY APPLN. INFO.:			JP 1999-81767	A 19990325
OTHER SOURCE(S):	MARPAT 133:252312			
GI				



AB The title compds. I [R1 and R2 are each independently hydrogen or C1-C6 alkyl; R3 is hydroxyl, etc.; R4 is hydrogen or R3R4 = bond; R6 is hydrogen, C1-C6 alkyl, or C3-C6 cycloalkyl; R7 is hydrogen, halogeno, nitro, formamido, amino, C1-C6 alkylcarbonylamino, etc.; R5 is pyridyl or phenyl; R8 is hydrogen or C1-C4 alkyl; n is an integer of 0 to 4; X is CH2, SO2, etc. ; and W is an optionally substituted aromatic group or a group derived from a cyclic amide whose ring is constituted of 5 to 7 members] are prepared (3R,4S)-6-(4-Methoxyphenylacetyl-amido)-3,4-dihydro-2,2-dimethyl-3-hydroxy-7-nitro-2H-1-benzopyran-4-(4-fluorobenzenesulfonyl)amide at 10  $\mu$ M gave a refractory period prolongation rate of 33%. Formulations are given.

REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 5 OF 6 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1998:102859 HCAPLUS

DOCUMENT NUMBER: 128:167351

TITLE: Preparation of 4-aminochroman derivatives having bradycardia activity for treating cardiac insufficiency in mammals

INVENTOR(S): Tanikawa, Keizo; Ohrai, Kazuhiko; Sato, Masayuki; Yamashita, Toru; Yanagihara, Kazufumi

PATENT ASSIGNEE(S): Nissan Chemical Industries, Ltd., Japan

SOURCE: PCT Int. Appl., 200 pp.  
CODEN: PIXXD2



DOCUMENT TYPE: Patent  
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

Updated Search

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9804542	A1	19980205	WO 1997-JP2583	19970725
W: AU, CA, CN, CZ, HU, IL, KR, LT, NO, NZ, RO, RU, SK, UA, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2261143	AA	19980205	CA 1997-2261143	19970725
ZA 9706654	A	19980210	ZA 1997-6654	19970725
AU 9736349	A1	19980220	AU 1997-36349	19970725
AU 713573	B2	19991202		
JP 10087650	A2	19980407	JP 1997-199707	19970725
EP 934296	A1	19990811	EP 1997-933023	19970725
EP 934296	B1	20030604		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
CN 1226243	A	19990818	CN 1997-196736	19970725
NZ 333870	A	20000825	NZ 1997-333870	19970725
TW 491844	B	20020621	TW 1997-86110615	19970725
AT 242230	E	20030615	AT 1997-933023	19970725
KR 2000023843	A	20000425	KR 1999-700359	19990118
US 6066631	A	20000523	US 1999-232645	19990119
NO 9900265	A	19990325	NO 1999-265	19990121
LT 4578	B	19991125	LT 1999-17	19990223
PRIORITY APPLN. INFO.:			JP 1996-197819	A 19960726
OTHER SOURCE(S):			WO 1997-JP2583	W 19970725
GI				
MARPAT 128:167351				



AB The present invention relates to chroman derivs. of formula [I; R1 = H, halo, (un)substituted C1-6 alkyl, alkoxy, C3-6 cycloalkyl, NO<sub>2</sub>, cyano, CHO, CO<sub>2</sub>H, OH, NHCHO, (un)substituted NH<sub>2</sub>, etc.; R3, R4 = H, (un)substituted C1-6 alkyl; or CR<sub>3</sub>R<sub>4</sub> forms C3-6 cycloalkyl; R5 = HO or C1-6 alkylcarbonyloxy, or it forms a bond together with R5; R6 = H or it forms a bond together with R5; R7, R8 = H, (un)substituted C1-6 alkyl, C2-6 alkenyl, alkynyl, or C3-6 cycloalkyl, etc.; or R7 and R8 together form (un)substituted 1,4-butylene or 1,5-pentylene, etc.; n = 0 or an

10541677

integer of 1, 2, 3, or 4; W = (un)substituted Ph, pyridyl, pyrimidinyl, furanyl, thiofuranyl, pyrrolyl, indolyl, or naphthyl, etc.; X = CO, CH<sub>2</sub>, SO<sub>2</sub>, (un)substituted NH; Y = (un)substituted NH when X = CO, CH<sub>2</sub>, or SO<sub>2</sub>; Y = CO when X = (un)substituted NH; Z = absent or CH<sub>2</sub> or (un)substituted NH] or their salts and medicines for curing cardiac insufficiency containing as an active ingredient the chroman derivative I or their salts. These compds. show cardiotoxic activity and caused neg. chronotropic action in a concentration-dependent manner and are useful drugs for the treatment of heart failure. Thus, an ethanolic solution of 6-(benzoylamino)-3,4-epoxy-3,4-dihydro-2,2-dimethyl-7-nitro-2H-1-benzopyran was added with pyrrolidine and heated under reflux for 2 h to give a 4-(1-pyrrolidinyl) benzopyran (II; R = PhCONH). II (R = PhNHCONH) in vitro decreased heart rate of male Hartley guinea pig's heart by 10.1, 25.6, 65.9, and 87.6% at 10, 30, 100, and 300 µM, resp.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 6 OF 6 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1997:503449 HCAPLUS

DOCUMENT NUMBER: 127:104346

TITLE: Benzopyran compounds for the treatment of cardiac failure

INVENTOR(S): Tanikawa, Keizo; Ohrai, Kazuhiko; Sato, Masayuki; Yamashita, Toru

PATENT ASSIGNEE(S): Nissan Chemical Industries, Ltd., Japan

SOURCE: PCT Int. Appl., 42 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9723209	A1	19970703	WO 1996-JP3761	19961224
W: CA, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
JP 09235227	A2	19970909	JP 1996-344717	19961225
PRIORITY APPLN. INFO.:			JP 1995-335562	A 19951225

OTHER SOURCE(S): MARPAT 127:104346

AB A therapeutic agent for cardiac failure comprises a benzopyran derivative as an active ingredient. 7-Acetylamino-3,4-dihydro-2,2-dimethyl-6-nitro-trans-4-(1-pyrrolidinyl)-2H-1-benzopyran-3-ol (I) was prepared and formulated to tablets, capsules, ointments, suppositories, and injections. I decreased isoproterenol-induced heart rates of isolated hearts of guinea pigs.

=> s 134:237394/dn

L3 1 134:237394/DN

=> sel rn

E1 THROUGH E127 ASSIGNED

=> file reg

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
21.58	21.79

FULL ESTIMATED COST

Updated Search

10541677

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-4.50	-4.50

FILE 'REGISTRY' ENTERED AT 14:00:39 ON 16 OCT 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 15 OCT 2006 HIGHEST RN 910448-76-9  
DICTIONARY FILE UPDATES: 15 OCT 2006 HIGHEST RN 910448-76-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> s el-el27

- 1 100-46-9/BI  
(100-46-9/RN)
- 1 120-20-7/BI  
(120-20-7/RN)
- 1 13078-79-0/BI  
(13078-79-0/RN)
- 1 13078-80-3/BI  
(13078-80-3/RN)
- 1 13214-66-9/BI  
(13214-66-9/RN)
- 1 13258-63-4/BI  
(13258-63-4/RN)
- 1 13472-00-9/BI  
(13472-00-9/RN)
- 1 14573-23-0/BI  
(14573-23-0/RN)
- 1 150112-76-8/BI  
(150112-76-8/RN)
- 1 150112-77-9/BI  
(150112-77-9/RN)
- 1 156-41-2/BI  
(156-41-2/RN)
- 1 1583-88-6/BI  
(1583-88-6/RN)
- 1 17027-51-9/BI  
(17027-51-9/RN)
- 1 17283-14-6/BI  
(17283-14-6/RN)
- 1 20173-24-4/BI

Updated Search

(20173-24-4/RN)  
1 2038-57-5/BI  
(2038-57-5/RN)  
1 2039-67-0/BI  
(2039-67-0/RN)  
1 21581-45-3/BI  
(21581-45-3/RN)  
1 24954-67-4/BI  
(24954-67-4/RN)  
1 2706-56-1/BI  
(2706-56-1/RN)  
1 30433-91-1/BI  
(30433-91-1/RN)  
1 3213-28-3/BI  
(3213-28-3/RN)  
1 330599-96-7/BI  
(330599-96-7/RN)  
1 330599-97-8/BI  
(330599-97-8/RN)  
1 330599-98-9/BI  
(330599-98-9/RN)  
1 330599-99-0/BI  
(330599-99-0/RN)  
1 330600-00-5/BI  
(330600-00-5/RN)  
1 330600-01-6/BI  
(330600-01-6/RN)  
1 330600-02-7/BI  
(330600-02-7/RN)  
1 330600-03-8/BI  
(330600-03-8/RN)  
1 330600-04-9/BI  
(330600-04-9/RN)  
1 330600-05-0/BI  
(330600-05-0/RN)  
1 330600-06-1/BI  
(330600-06-1/RN)  
1 330600-07-2/BI  
(330600-07-2/RN)  
1 330600-08-3/BI  
(330600-08-3/RN)  
1 330600-09-4/BI  
(330600-09-4/RN)  
1 330600-10-7/BI  
(330600-10-7/RN)  
1 330600-11-8/BI  
(330600-11-8/RN)  
1 330600-12-9/BI  
(330600-12-9/RN)  
1 330600-13-0/BI  
(330600-13-0/RN)  
1 330600-14-1/BI  
(330600-14-1/RN)  
1 330600-15-2/BI  
(330600-15-2/RN)  
1 330600-16-3/BI  
(330600-16-3/RN)  
1 330600-17-4/BI  
(330600-17-4/RN)

10541677

1 330600-18-5/BI  
(330600-18-5/RN)  
1 330600-19-6/BI  
(330600-19-6/RN)  
1 330600-20-9/BI  
(330600-20-9/RN)  
1 330600-21-0/BI  
(330600-21-0/RN)  
1 330600-22-1/BI  
(330600-22-1/RN)  
1 330600-23-2/BI  
(330600-23-2/RN)  
1 330600-24-3/BI  
(330600-24-3/RN)  
1 330600-25-4/BI  
(330600-25-4/RN)  
1 330600-26-5/BI  
(330600-26-5/RN)  
1 330600-27-6/BI  
(330600-27-6/RN)  
1 330600-28-7/BI  
(330600-28-7/RN)  
1 330600-29-8/BI  
(330600-29-8/RN)  
1 330600-30-1/BI  
(330600-30-1/RN)  
1 330600-31-2/BI  
(330600-31-2/RN)  
1 330600-32-3/BI  
(330600-32-3/RN)  
1 330600-33-4/BI  
(330600-33-4/RN)  
1 330600-34-5/BI  
(330600-34-5/RN)  
1 330600-35-6/BI  
(330600-35-6/RN)  
1 330600-36-7/BI  
(330600-36-7/RN)  
1 330600-37-8/BI  
(330600-37-8/RN)  
1 330600-38-9/BI  
(330600-38-9/RN)  
1 330600-39-0/BI  
(330600-39-0/RN)  
1 330600-40-3/BI  
(330600-40-3/RN)  
1 330600-41-4/BI  
(330600-41-4/RN)  
1 330600-42-5/BI  
(330600-42-5/RN)  
1 330600-43-6/BI  
(330600-43-6/RN)  
1 330600-44-7/BI  
(330600-44-7/RN)  
1 330600-45-8/BI  
(330600-45-8/RN)  
1 330600-46-9/BI  
(330600-46-9/RN)  
1 330600-47-0/BI

Updated Search

(330600-47-0/RN)  
1 330600-48-1/BI  
(330600-48-1/RN)  
1 330600-49-2/BI  
(330600-49-2/RN)  
1 330600-50-5/BI  
(330600-50-5/RN)  
1 330600-51-6/BI  
(330600-51-6/RN)  
1 330600-52-7/BI  
(330600-52-7/RN)  
1 330600-53-8/BI  
(330600-53-8/RN)  
1 330600-54-9/BI  
(330600-54-9/RN)  
1 330600-55-0/BI  
(330600-55-0/RN)  
1 330600-56-1/BI  
(330600-56-1/RN)  
1 330600-57-2/BI  
(330600-57-2/RN)  
1 330600-58-3/BI  
(330600-58-3/RN)  
1 330600-59-4/BI  
(330600-59-4/RN)  
1 330600-60-7/BI  
(330600-60-7/RN)  
1 330600-61-8/BI  
(330600-61-8/RN)  
1 330600-63-0/BI  
(330600-63-0/RN)  
1 330600-64-1/BI  
(330600-64-1/RN)  
1 330600-65-2/BI  
(330600-65-2/RN)  
1 330600-66-3/BI  
(330600-66-3/RN)  
1 330600-67-4/BI  
(330600-67-4/RN)  
1 330600-68-5/BI  
(330600-68-5/RN)  
1 330600-69-6/BI  
(330600-69-6/RN)  
1 330600-70-9/BI  
(330600-70-9/RN)  
1 330600-71-0/BI  
(330600-71-0/RN)  
1 330600-72-1/BI  
(330600-72-1/RN)  
1 330600-73-2/BI  
(330600-73-2/RN)  
1 330600-74-3/BI  
(330600-74-3/RN)  
1 330600-75-4/BI  
(330600-75-4/RN)  
1 330600-76-5/BI  
(330600-76-5/RN)  
1 330600-77-6/BI  
(330600-77-6/RN)

1 330600-78-7/BI  
 (330600-78-7/RN)  
 1 330600-79-8/BI  
 (330600-79-8/RN)  
 1 330600-80-1/BI  
 (330600-80-1/RN)  
 1 330600-81-2/BI  
 (330600-81-2/RN)  
 1 330600-82-3/BI  
 (330600-82-3/RN)  
 1 330600-83-4/BI  
 (330600-83-4/RN)  
 1 36377-59-0/BI  
 (36377-59-0/RN)  
 1 3963-62-0/BI  
 (3963-62-0/RN)  
 1 404-70-6/BI  
 (404-70-6/RN)  
 1 51-67-2/BI  
 (51-67-2/RN)  
 1 52516-13-9/BI  
 (52516-13-9/RN)  
 1 52516-30-0/BI  
 (52516-30-0/RN)  
 1 52721-69-4/BI  
 (52721-69-4/RN)  
 1 55-81-2/BI  
 (55-81-2/RN)  
 1 55536-65-7/BI  
 (55536-65-7/RN)  
 1 582-22-9/BI  
 (582-22-9/RN)  
 1 61-54-1/BI  
 (61-54-1/RN)  
 1 62-53-3/BI  
 (62-53-3/RN)  
 1 62885-82-9/BI  
 (62885-82-9/RN)  
 1 64-04-0/BI  
 (64-04-0/RN)  
 1 64-12-0/BI  
 (64-12-0/RN)  
 1 73918-56-6/BI  
 (73918-56-6/RN)  
 1 78939-06-7/BI  
 (78939-06-7/RN)  
 1 86456-97-5/BI  
 (86456-97-5/RN)

L4


127 (100-46-9/BI OR 120-20-7/BI OR 13078-79-0/BI OR 13078-80-3/BI  
 OR 13214-66-9/BI OR 13258-63-4/BI OR 13472-00-9/BI OR 14573-23-0  
 /BI OR 150112-76-8/BI OR 150112-77-9/BI OR 156-41-2/BI OR 1583-88  
 -6/BI OR 17027-51-9/BI OR 17283-14-6/BI OR 20173-24-4/BI OR 2038-  
 57-5/BI OR 2039-67-0/BI OR 21581-45-3/BI OR 24954-67-4/BI OR  
 2706-56-1/BI OR 30433-91-1/BI OR 3213-28-3/BI OR 330599-96-7/BI  
 OR 330599-97-8/BI OR 330599-98-9/BI OR 330599-99-0/BI OR 330600-0  
 0-5/BI OR 330600-01-6/BI OR 330600-02-7/BI OR 330600-03-8/BI OR  
 330600-04-9/BI OR 330600-05-0/BI OR 330600-06-1/BI OR 330600-07-2  
 /BI OR 330600-08-3/BI OR 330600-09-4/BI OR 330600-10-7/BI OR  
 330600-11-8/BI OR 330600-12-9/BI OR 330600-13-0/BI OR 330600-14-1

10541677

/BI OR 330600-15-2/BI OR 330600-16-3/BI OR 330600-17-4/BI OR  
330600-18-5/BI OR 330600-19-6/BI OR 330600-20-9/BI OR 330600-21-0  
/BI OR 330600-22-1/BI OR 330600-23-2/BI OR 330600-24-3/BI OR  
330600-25-4/BI OR 330600-26-5/BI OR 330600-27-6/BI OR 330600-28-7  
/BI OR 330600-29-8/BI OR 330600-30-1

=> d scan

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Benzeneethanamine, 2-fluoro- (9CI)  
MF C8 H10 F N  
CI COM




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):100

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Acetamide, N-[(3R,4S)-3,4-dihydro-3-hydroxy-2,2-dimethyl-7-nitro-4-[[2-(2-pyridinyl)ethyl]amino]-2H-1-benzopyran-6-yl]-, rel- (9CI)  
MF C20 H24 N4 O5

Relative stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Cyclopropanecarboxamide, N-[(3R,4S)-3,4-dihydro-3-hydroxy-4-[[2-(4-methoxyphenyl)ethyl]amino]-2,2-dimethyl-7-nitro-2H-1-benzopyran-6-yl]-,

Updated Search

10541677


rel- (9CI)  
MF C24 H29 N3 O6

Relative stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN 2H-Oxireno[c][1]benzopyran-6-amine, N-ethyl-1a,7b-dihydro-2,2-dimethyl-5-nitro- (9CI)  
MF C13 H16 N2 O4



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN 3-Pyridineethanamine (9CI)  
MF C7 H10 N2  
CI COM




Updated Search

10541677

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Acetamide, N-[(3R,4S)-4-[[2-(3,4-dimethylphenyl)ethyl]amino]-3,4-dihydro-3-hydroxy-2,2-dimethyl-7-nitro-2H-1-benzopyran-6-yl]-, rel- (9CI)  
MF C23 H29 N3 O5

Relative stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Propanamide, N-[(3R,4S)-4-[[2-(4-chlorophenyl)ethyl]amino]-3,4-dihydro-3-hydroxy-2,2-dimethyl-7-nitro-2H-1-benzopyran-6-yl]-2-methyl-, monohydrochloride, rel- (9CI)  
MF C23 H28 Cl N3 O5 . Cl H

Relative stereochemistry.

Updated Search


10541677



● HCl

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Propanamide, N-[(3R,4S)-4-[[2-(4-fluorophenyl)ethyl]amino]-3,4-dihydro-3-hydroxy-2,2-dimethyl-7-nitro-2H-1-benzopyran-6-yl]-2-methyl-, monohydrochloride, rel-(-)- (9CI)  
MF C23 H28 F N3 O5 . Cl H

Rotation (-). Absolute stereochemistry unknown.




● HCl

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Benzeneethanamine, 2-chloro- (9CI)  
MF C8 H10 Cl N  
CI COM

Updated Search


10541677



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Acetamide, N-[(3R,4S)-4-[[2-(2-fluorophenyl)ethyl]amino]-3,4-dihydro-3-hydroxy-2,2-dimethyl-7-nitro-2H-1-benzopyran-6-yl]-, rel- (9CI)  
MF C21 H24 F N3 O5

Relative stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Propanamide, N-[(3R,4S)-4-[[2-(3,5-dimethoxyphenyl)ethyl]amino]-3,4-dihydro-3-hydroxy-2,2-dimethyl-7-nitro-2H-1-benzopyran-6-yl]-2-methyl-, monohydrochloride, rel- (9CI)  
MF C25 H33 N3 O7 . Cl H

Relative stereochemistry.

Updated Search


10541677



● HCl

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Acetamide, N-[(3R,4S)-4-[[2-(4-fluorophenyl)ethyl]amino]-3,4-dihydro-3-hydroxy-2,2-dimethyl-7-nitro-2H-1-benzopyran-6-yl]- (9CI)  
MF C21 H24 F N3 O5

Absolute stereochemistry. Rotation (-).




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Benzeneethanamine, 4-fluoro- (9CI)  
MF C8 H10 F N  
CI COM

Updated Search


10541677



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Acetamide, N-[(3R,4S)-3,4-dihydro-3-hydroxy-2,2-dimethyl-7-nitro-4-[(3-phenylpropyl)amino]-2H-1-benzopyran-6-yl]-, rel- (9CI)  
MF C22 H27 N3 O5


Relative stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Acetamide, N-[(3R,4S)-3,4-dihydro-3-hydroxy-2,2-dimethyl-7-nitro-4-[[2-[3-(trifluoromethyl)phenyl]ethyl]amino]-2H-1-benzopyran-6-yl]-, rel- (9CI)  
MF C22 H24 F3 N3 O5

Relative stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

Updated Search

10541677


L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Cyclopropanecarboxamide, N-[(3R,4S)-3,4-dihydro-3-hydroxy-2,2-dimethyl-7-nitro-4-[(2-phenylethyl)amino]-2H-1-benzopyran-6-yl]-, rel- (9CI)  
MF C23 H27 N3 O5

Relative stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Benzeneethanamine (9CI)  
MF C8 H11 N  
CI COM



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Benzeneethanamine, 4-ethoxy- (9CI)  
MF C10 H15 N O  
CI COM




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Acetamide, N-[(3R,4S)-4-[(2-[1,1'-biphenyl]-4-ylethyl)amino]-3,4-dihydro-3-hydroxy-2,2-dimethyl-7-nitro-2H-1-benzopyran-6-yl]-, rel- (9CI)  
MF C27 H29 N3 O5

Updated Search

10541677


Relative stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Cyclopropanecarboxamide, N-[(3R,4S)-4-[[2-(3-fluorophenyl)ethyl]amino]-3,4-dihydro-3-hydroxy-2,2-dimethyl-7-nitro-2H-1-benzopyran-6-yl]-, rel- (9CI)  
MF C23 H26 F N3 O5

Relative stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Cyclopropanecarboxamide, N-(1a,7b-dihydro-2,2-dimethyl-5-nitro-2H-oxireno[c][1]benzopyran-6-yl)-, (+)- (9CI)  
MF C15 H16 N2 O5

Updated Search


10541677

Rotation (+).



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Benzeneethanamine, 4-nitro- (9CI)  
MF C8 H10 N2 O2  
CI COM




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Acetamide, N-[(3R,4S)-4-[[2-(3-ethoxy-4-methoxyphenyl)ethyl]amino]-3,4-dihydro-3-hydroxy-2,2-dimethyl-7-nitro-2H-1-benzopyran-6-yl]-, rel- (9CI)  
MF C24 H31 N3 O7

Relative stereochemistry.

Updated Search


10541677



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Propanamide, N-[(3R,4S)-4-[[2-(4-aminophenyl)ethyl]amino]-3,4-dihydro-3-hydroxy-2,2-dimethyl-7-nitro-2H-1-benzopyran-6-yl]-2-methyl-, monohydrochloride, rel- (9CI)  
MF C23 H30 N4 O5 . Cl H

Relative stereochemistry.




● HCl

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Propanamide, N-(1a,7b-dihydro-2,2-dimethyl-5-nitro-2H-oxireno[c][1]benzopyran-6-yl)-2-methyl- (9CI)  
MF C15 H18 N2 O5


Updated Search

10541677



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN 4-Pyridineethanamine (9CI)  
MF C7 H10 N2  
CI COM



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Acetamide, N-[(3R,4S)-4-[[2-(4-fluorophenyl)ethyl]amino]-3,4-dihydro-3-hydroxy-2,2-dimethyl-7-nitro-2H-1-benzopyran-6-yl]-, rel- (9CI)  
MF C<sub>21</sub> H<sub>24</sub> F N<sub>3</sub> O<sub>5</sub>

Relative stereochemistry.




Updated Search

10541677

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Propanamide, N-[(3R,4S)-3,4-dihydro-3-hydroxy-2,2-dimethyl-7-nitro-4-[[2-[3-(trifluoromethyl)phenyl]ethyl]amino]-2H-1-benzopyran-6-yl]-2-methyl-, monohydrochloride, rel- (9CI)  
MF C24 H28 F3 N3 O5 . Cl H

Relative stereochemistry.



L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Acetamide, N-[(3R,4S)-3,4-dihydro-3-hydroxy-2,2-dimethyl-7-nitro-4-[(2-phenylethyl)amino]-2H-1-benzopyran-6-yl]-2,2,2-trifluoro-, rel-(-)- (9CI)  
MF C21 H22 F3 N3 O5

Rotation (-). Absolute stereochemistry unknown.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Benzenethanamine, 3-methoxy- (9CI)  
MF C9 H13 N O

Updated Search

10541677


CI COM



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Acetamide, N-[(3R,4S)-3,4-dihydro-3-hydroxy-4-[[2-(4-hydroxyphenyl)ethyl]amino]-2,2-dimethyl-7-nitro-2H-1-benzopyran-6-yl]-, rel- (9CI)  
MF C21 H25 N3 O6

Relative stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Acetamide, N-[(3R,4S)-3,4-dihydro-3-hydroxy-2,2-dimethyl-7-nitro-4-(phenylamino)-2H-1-benzopyran-6-yl]-, rel- (9CI)  
MF C19 H21 N3 O5

Relative stereochemistry.

Updated Search


10541677



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Acetamide, N-[(3R,4S)-3,4-dihydro-3-hydroxy-2,2-dimethyl-7-nitro-4-[(2-phenylethyl)amino]-2H-1-benzopyran-6-yl]-2,2,2-trifluoro-, rel- (9CI)  
MF C21 H22 F3 N3 O5

Relative stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Benzenemethanamine (9CI)  
MF C7 H9 N  
CI COM


H<sub>2</sub>N-CH<sub>2</sub>-Ph

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Acetamide, N-(1a,7b-dihydro-2,2-dimethyl-5-nitro-2H-oxireno[c][1]benzopyran-6-yl)- (9CI)  
MF C13 H14 N2 O5

Updated Search


10541677



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Acetamide, N-[(3R,4S)-4-[[2-[3,4-bis(phenylmethoxy)phenyl]ethyl]amino]-3,4-dihydro-3-hydroxy-2,2-dimethyl-7-nitro-2H-1-benzopyran-6-yl]-, rel- (9CI)  
MF C35 H37 N3 O7

Relative stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Cyclopropanecarboxamide, N-[(3R,4S)-4-[[2-(3,5-dimethoxyphenyl)ethyl]amino]-3,4-dihydro-3-hydroxy-2,2-dimethyl-7-nitro-2H-1-benzopyran-6-yl]-, rel- (9CI)  
MF C25 H31 N3 O7

Relative stereochemistry.


10541677



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Propanamide, N-(1a,7b-dihydro-2,2-dimethyl-5-nitro-2H-oxireno[c][1]benzopyran-6-yl)-2-methyl-, (+) - (9CI)  
MF C15 H18 N2 O5

Rotation (+).



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Benzeneethanamine, 4-ethoxy-3-methoxy- (9CI)  
MF C11 H17 N O2  
CI COM




Updated Search

10541677

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Acetamide, N-[(3R,4S)-3,4-dihydro-3-hydroxy-2,2-dimethyl-7-nitro-4-[[2-(2-thienyl)ethyl]amino]-2H-1-benzopyran-6-yl]-, rel- (9CI)  
MF C19 H23 N3 O5 S


Relative stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Cyclopropanecarboxamide, N-[(3R,4S)-3,4-dihydro-3-hydroxy-2,2-dimethyl-7-nitro-4-[[2-(4-nitrophenyl)ethyl]amino]-2H-1-benzopyran-6-yl]-, rel- (9CI)  
MF C23 H26 N4 O7

Relative stereochemistry.




Updated Search

10541677


\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Propanamide, N-(1a,7b-dihydro-2,2-dimethyl-5-nitro-2H-oxireno[c][1]benzopyran-6-yl)-2,2-dimethyl- (9CI)  
MF C16 H20 N2 O5



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Benzeneethanamine, 2,6-dichloro- (9CI)  
MF C8 H9 Cl2 N  
CI COM




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Acetamide, N-[(3R,4S)-3,4-dihydro-3-hydroxy-4-[[2-(3-methoxyphenyl)ethyl]amino]-2,2-dimethyl-7-nitro-2H-1-benzopyran-6-yl]-, rel- (9CI)  
MF C22 H27 N3 O6

Relative stereochemistry.

Updated Search


10541677



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Propanamide, N-[(3R,4S)-4-[[2-(3-fluorophenyl)ethyl]amino]-3,4-dihydro-3-hydroxy-2,2-dimethyl-7-nitro-2H-1-benzopyran-6-yl]-2-methyl-, monohydrochloride, rel- (9CI)  
MF C23 H28 F N3 O5 . Cl H

Relative stereochemistry.




● HCl

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Acetamide, N-[(3S,4R)-3,4-dihydro-3-hydroxy-2,2-dimethyl-7-nitro-4-[(2-phenylethyl)amino]-2H-1-benzopyran-6-yl]- (9CI)  
MF C21 H25 N3 O5

Absolute stereochemistry. Rotation (+).


Updated Search

10541677



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Benzeneethanamine, 3,5-dimethoxy- (9CI)  
MF C10 H15 N O2  
CI COM



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Acetamide, N-[(3R,4S)-4-[[2-(4-chlorophenyl)ethyl]amino]-3,4-dihydro-3-hydroxy-2,2-dimethyl-7-nitro-2H-1-benzopyran-6-yl]-, rel- (9CI)  
MF C21 H24 Cl N3 O5

Relative stereochemistry.




Updated Search

10541677

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Acetamide, N-[(3S,4R)-4-[[[(1R)-2-(4-chlorophenyl)-1-methylethyl]amino]-3,4-dihydro-3-hydroxy-2,2-dimethyl-7-nitro-2H-1-benzopyran-6-yl]-, rel- (9CI)  
MF C22 H26 Cl N3 O5


Relative stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN 2H-1-Benzopyran-3-ol, 6-(ethylamino)-3,4-dihydro-2,2-dimethyl-7-nitro-4-[(2-phenylethyl)amino]-, (3R,4S)-rel- (9CI)  
MF C21 H27 N3 O4

Relative stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Benzeneethanamine, 4-chloro- (9CI)  
MF C8 H10 Cl N  
CI COM

Updated Search


10541677



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Acetamide, N-[(1aS,7bS)-1a,7b-dihydro-2,2-dimethyl-5-nitro-2H-oxireno[c][1]benzopyran-6-yl]- (9CI)  
MF C13 H14 N2 O5


Absolute stereochemistry. Rotation (+).



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Acetamide, N-[(3R,4S)-4-[[2-(4-ethoxyphenyl)ethyl]amino]-3,4-dihydro-3-hydroxy-2,2-dimethyl-7-nitro-2H-1-benzopyran-6-yl]-, rel- (9CI)  
MF C23 H29 N3 O6

Relative stereochemistry.




Updated Search

10541677

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Cyclopropanecarboxamide, N-[(3R,4S)-4-[[2-(4-aminophenyl)ethyl]amino]-3,4-dihydro-3-hydroxy-2,2-dimethyl-7-nitro-2H-1-benzopyran-6-yl]-, rel- (9CI)  
MF C23 H28 N4 O5

Relative stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Benzeneethanamine, 4-methoxy- (9CI)  
MF C9 H13 N O  
CI COM



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Benzeneethanamine, 3-(trifluoromethyl)- (9CI)  
MF C9 H10 F3 N  
CI COM

Updated Search


FC(F)(F)c1ccc(cc1)CCN

```
L4 127 ANSWERS  REGISTRY  COPYRIGHT 2006 ACS on STN
IN  Acetamide, N-[(3R,4S)-3,4-dihydro-3-hydroxy-2,2-dimethyl-7-nitro-4-[[2-(3-
MF  pyridinyl)ethyl]amino]-2H-1-benzopyran-6-yl]-, rel- (9CI)
    C20 H24 N4 O5
```

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Cyclopropanecarboxamide, N-[(3R,4S)-4-[[2-(2-fluorophenyl)ethyl]amino]-3,4-  
MF dihydro-3-hydroxy-2,2-dimethyl-7-nitro-2H-1-benzopyran-6-yl]-, rel- (9CI)  
C23 H26 F N3 O5


Updated Search

10541677




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Acetamide, N-(1a,7b-dihydro-2,2-dimethyl-5-nitro-2H-oxireno[c][1]benzopyran-6-yl)-N-ethyl- (9CI)  
MF C15 H18 N2 O5



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Benzeneethanamine, 3,4-dimethyl- (9CI)  
MF C10 H15 N  
CI COM




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

Updated Search

10541677

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Acetamide, N-[(3R,4S)-4-[[2-(4-bromophenyl)ethyl]amino]-3,4-dihydro-3-hydroxy-2,2-dimethyl-7-nitro-2H-1-benzopyran-6-yl]-, rel- (9CI)  
MF C21 H24 Br N3 O5


Relative stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Propanamide, N-[(3R,4S)-3,4-dihydro-3-hydroxy-2,2-dimethyl-7-nitro-4-[(3-phenylpropyl)amino]-2H-1-benzopyran-6-yl]-2-methyl-, monohydrochloride, rel- (9CI)  
MF C24 H31 N3 O5 . Cl H

Relative stereochemistry.




● HCl

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Acetamide, N-[(3S,4R)-4-[[2-(2-fluorophenyl)ethyl]amino]-3,4-dihydro-3-hydroxy-2,2-dimethyl-7-nitro-2H-1-benzopyran-6-yl]- (9CI)  
MF C21 H24 F N3 O5

Absolute stereochemistry. Rotation (+).


Updated Search

10541677



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Benzeneethanamine, 3-chloro- (9CI)  
MF C8 H10 Cl N  
CI COM




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Acetamide, N-[(3R,4S)-3,4-dihydro-3-hydroxy-2,2-dimethyl-7-nitro-4-[[2-(4-nitrophenyl)ethyl]amino]-2H-1-benzopyran-6-yl]-, rel- (9CI)  
MF C<sub>21</sub> H<sub>24</sub> N<sub>4</sub> O<sub>7</sub>

Relative stereochemistry.

Updated Search


10541677



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Propanamide, N-[(3R,4S)-3,4-dihydro-3-hydroxy-2,2-dimethyl-7-nitro-4-[[2-(4-nitrophenyl)ethyl]amino]-2H-1-benzopyran-6-yl]-2-methyl-, monohydrochloride, rel- (9CI)  
MF C23 H28 N4 O7 . Cl H

Relative stereochemistry.




● HCl

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Acetamide, N-[(3R,4S)-3,4-dihydro-3-hydroxy-2,2-dimethyl-7-nitro-4-[(phenylmethyl)amino]-2H-1-benzopyran-6-yl]- (9CI)  
MF C20 H23 N3 O5

Absolute stereochemistry. Rotation (+).


Updated Search

10541677



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Benzeneethanamine,  $\beta$ -methyl- (9CI)  
MF C9 H13 N  
CI COM



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Acetamide, N-[(3R,4S)-3,4-dihydro-3-hydroxy-2,2-dimethyl-7-nitro-4-[(2-phenylethyl)amino]-2H-1-benzopyran-6-yl]-, rel- (9CI)  
MF C21 H25 N3 O5

Relative stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Acetamide, N-[(3R,4S)-4-[[2-(3-chlorophenyl)ethyl]amino]-3,4-dihydro-3-hydroxy-2,2-dimethyl-7-nitro-2H-1-benzopyran-6-yl]-, rel- (9CI)  
MF C21 H24 Cl N3 O5

Updated Search

10541677


Relative stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Cyclopropanecarboxamide, N-[(3R,4S)-3,4-dihydro-3-hydroxy-2,2-dimethyl-7-nitro-4-[[2-[3-(trifluoromethyl)phenyl]ethyl]amino]-2H-1-benzopyran-6-yl]-, rel- (9CI)  
MF C24 H26 F3 N3 O5

Relative stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Benzenamine (9CI)

Updated Search


10541677

MF C6 H7 N  
CI COM




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Benzeneethanamine, 3,4-bis(phenylmethoxy) - (9CI)  
MF C22 H23 N O2  
CI COM



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Acetamide, N-[(3R,4S)-3,4-dihydro-3-hydroxy-4-[[2-(1H-indol-3-yl)ethyl]amino]-2,2-dimethyl-7-nitro-2H-1-benzopyran-6-yl]-, rel- (9CI)  
MF C23 H26 N4 O5




Updated Search

10541677


L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Cyclopropanecarboxamide, N-[(3R,4S)-4-[[2-(4-fluorophenyl)ethyl]amino]-3,4-dihydro-3-hydroxy-2,2-dimethyl-7-nitro-2H-1-benzopyran-6-yl]-, rel- (9CI)  
MF C23 H26 F N3 O5

Relative stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Formamide, N-(1a,7b-dihydro-2,2-dimethyl-5-nitro-2H-oxireno[c][1]benzopyran-6-yl)- (9CI)  
MF C12 H12 N2 O5




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Benzeneethanamine, 3,4-dichloro- (9CI)  
MF C8 H9 Cl2 N  
CI COM

Updated Search


10541677



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Acetamide, N-[(3R,4S)-4-[(2,2-diphenylethyl)amino]-3,4-dihydro-3-hydroxy-2,2-dimethyl-7-nitro-2H-1-benzopyran-6-yl]-, rel- (9CI)  
MF C27 H29 N3 O5

Relative stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Propanamide, N-[(3R,4S)-4-[[2-(3-chlorophenyl)ethyl]amino]-3,4-dihydro-3-hydroxy-2,2-dimethyl-7-nitro-2H-1-benzopyran-6-yl]-2-methyl-, monohydrochloride, rel- (9CI)  
MF C23 H28 Cl N3 O5 . Cl H

Relative stereochemistry.

Updated Search


10541677



● HCl

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Acetamide, N- [(3R,4S)-4- [[ (1R)-2- (4-chlorophenyl)-1-methylethyl]amino]-3,4-dihydro-3-hydroxy-2,2-dimethyl-7-nitro-2H-1-benzopyran-6-yl]-, rel- (9CI)  
MF C22 H26 Cl N3 O5

Relative stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Benzenebutanamine (9CI)  
MF C10 H15 N  
CI COM

H<sub>2</sub>N- (CH<sub>2</sub>)<sub>4</sub>- Ph


Updated Search

10541677

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Acetamide, N-[(3R,4S)-4-[[2-(3-fluorophenyl)ethyl]amino]-3,4-dihydro-3-hydroxy-2,2-dimethyl-7-nitro-2H-1-benzopyran-6-yl]-, rel- (9CI)  
MF C21 H24 F N3 O5

Relative stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Propanamide, N-[(3R,4S)-4-[[2-(2-fluorophenyl)ethyl]amino]-3,4-dihydro-3-hydroxy-2,2-dimethyl-7-nitro-2H-1-benzopyran-6-yl]-2-methyl-, monohydrochloride, rel- (9CI)  
MF C23 H28 F N3 O5 . Cl H

Relative stereochemistry.


10541677



● HCl

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Cyclopropanecarboxamide, N-[(3R,4S)-4-[[2-(4-fluorophenyl)ethyl]amino]-3,4-dihydro-3-hydroxy-2,2-dimethyl-7-nitro-2H-1-benzopyran-6-yl]-, monohydrochloride, rel-(-)- (9CI)  
MF C23 H26 F N3 O5 . Cl H

Rotation (-). Absolute stereochemistry unknown.



● HCl

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Benzenepropanamine (9CI)  
MF C9 H13 N  
CI COM

Updated Search


10541677

H<sub>2</sub>N-(CH<sub>2</sub>)<sub>3</sub>-Ph

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Acetamide, N-[(3R,4S)-3,4-dihydro-3-hydroxy-2,2-dimethyl-7-nitro-4-[(4-phenylbutyl)amino]-2H-1-benzopyran-6-yl]-, rel- (9CI)  
MF C23 H29 N3 O5


Relative stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Acetamide, N-[[2-(2,6-dichlorophenyl)ethyl]amino]-3,4-dihydro-3-hydroxy-2,2-dimethyl-7-nitro-2H-1-benzopyran-6-yl]-, rel- (9CI)  
MF C21 H23 Cl2 N3 O5

Relative stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN

Updated Search

10541677


IN Propanamide, N-[(3R,4S)-3,4-dihydro-3-hydroxy-2,2-dimethyl-7-nitro-4-[(2-phenylethyl)amino]-2H-1-benzopyran-6-yl]-2,2-dimethyl-, rel- (9CI)  
MF C24 H31 N3 O5

Relative stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Benzeneethanamine, 4-chloro- $\alpha$ -methyl- (9CI)  
MF C9 H12 Cl N  
CI COM



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Benzeneethanamine, 4-bromo- (9CI)  
MF C8 H10 Br N  
CI COM



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Acetamide, N-[(3R,4S)-4-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-3,4-dihydro-

Updated Search

10541677

3-hydroxy-2,2-dimethyl-7-nitro-2H-1-benzopyran-6-yl]-, rel- (9CI)  
MF C23 H29 N3 O7


Relative stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Cyclopropanecarboxamide, N-[(3R,4S)-4-[[2-(4-chlorophenyl)ethyl]amino]-3,4-dihydro-3-hydroxy-2,2-dimethyl-7-nitro-2H-1-benzopyran-6-yl]-, rel- (9CI)  
MF C23 H26 Cl N3 O5

Relative stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

Updated Search

10541677


L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Acetamide, N-(1a,7b-dihydro-2,2-dimethyl-5-nitro-2H-oxireno[c][1]benzopyran-6-yl)-2,2,2-trifluoro-, (+)- (9CI)  
MF C13 H11 F3 N2 O5

Rotation (+).



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN 2-Thiopheneethanamine (9CI)  
MF C6 H9 N S  
CI COM




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Acetamide, N-[(3R,4S)-4-[[2-(2,4-dichlorophenyl)ethyl]amino]-3,4-dihydro-3-hydroxy-2,2-dimethyl-7-nitro-2H-1-benzopyran-6-yl]-, rel- (9CI)  
MF C21 H23 Cl2 N3 O5

Relative stereochemistry.


10541677



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Propanamide, N-[(3R,4S)-3,4-dihydro-3-hydroxy-2,2-dimethyl-7-nitro-4-[(2-phenylethyl)amino]-2H-1-benzopyran-6-yl]-2-methyl-, monohydrochloride, rel- (9CI)  
MF C23 H29 N3 O5 . Cl H

Relative stereochemistry.



● HCl

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Cyclopropanecarboxamide, N-(1a,7b-dihydro-2,2-dimethyl-5-nitro-2H-oxireno[c][1]benzopyran-6-yl)- (9CI)  
MF C15 H16 N2 O5




Updated Search

10541677

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Benzeneethanamine, 4-amino- (9CI)  
MF C8 H12 N2  
CI COM



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Acetamide, N-[(3R,4S)-4-[[2-(3,5-dimethoxyphenyl)ethyl]amino]-3,4-dihydro-3-hydroxy-2,2-dimethyl-7-nitro-2H-1-benzopyran-6-yl]-, rel- (9CI)  
MF C23 H29 N3 O7

Relative stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Propanamide, N-[(3R,4S)-3,4-dihydro-3-hydroxy-4-[[2-(4-methoxyphenyl)ethyl]amino]-2,2-dimethyl-7-nitro-2H-1-benzopyran-6-yl]-2-methyl-, monohydrochloride, rel- (9CI)  
MF C24 H31 N3 O6 . Cl H

Relative stereochemistry.

Updated Search


10541677



● HCl

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Acetamide, N-[(3R,4S)-3,4-dihydro-3-hydroxy-2,2-dimethyl-7-nitro-4-[(2-phenylethyl)amino]-2H-1-benzopyran-6-yl]- (9CI)  
MF C21 H25 N3 O5


Absolute stereochemistry. Rotation (-).



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):28

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN 2-Pyridineethanamine (9CI)  
MF C7 H10 N2  
CI COM




Updated Search

10541677

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Acetamide, N-[(3R,4S)-3,4-dihydro-3-hydroxy-4-[[2-(4-methoxyphenyl)ethyl]amino]-2,2-dimethyl-7-nitro-2H-1-benzopyran-6-yl]-, rel- (9CI)  
MF C22 H27 N3 O6


Relative stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Acetamide, N-[(3R,4S)-3,4-dihydro-3-hydroxy-2,2-dimethyl-7-nitro-4-[(2-phenylpropyl)amino]-2H-1-benzopyran-6-yl]-, rel- (9CI)  
MF C22 H27 N3 O5

Relative stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

Updated Search

10541677


L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Acetamide, N-[(3R,4S)-3,4-dihydro-3-hydroxy-2,2-dimethyl-7-nitro-4-[(2-phenylethyl)amino]-2H-1-benzopyran-6-yl]-N-ethyl-, rel- (9CI)  
MF C23 H29 N3 O5

Relative stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Benzeneethanamine, 3,4-dimethoxy- (9CI)  
MF C10 H15 N O2  
CI COM



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Benzeneethanamine, 3-ethoxy-4-methoxy- (9CI)  
MF C11 H17 N O2  
CI COM



Updated Search

11454322

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal612bxx

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 AUG 09 INSPEC enhanced with 1898-1968 archive  
NEWS 4 AUG 28 ADISCTI Reloaded and Enhanced  
NEWS 5 AUG 30 CA(SM)/CAplus(SM) Austrian patent law changes  
NEWS 6- SEP 11 CA/CAplus enhanced with more pre-1907 records  
NEWS 7 SEP 21 CA/CAplus fields enhanced with simultaneous left and right  
truncation  
NEWS 8 SEP 25 CA(SM)/CAplus(SM) display of CA Lexicon enhanced  
NEWS 9 SEP 25 CAS REGISTRY(SM) no longer includes Concord 3D coordinates  
NEWS 10 SEP 25 CAS REGISTRY(SM) updated with amino acid codes for pyrrolysine  
NEWS 11 SEP 28 CEABA-VTB classification code fields reloaded with new  
classification scheme  
NEWS 12 OCT 19 The Derwent World Patents Index suite of databases on STN will  
be enhanced and reloaded on October 22, 2006.  
NEWS 13 OCT 19 LOGOFF HOLD duration extended to 120 minutes  
NEWS 14 OCT 19 E-mail format enhanced  
  
NEWS EXPRESS JUNE 30 CURRENT WINDOWS VERSION IS V8.01b, CURRENT  
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),  
AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.  
  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items  
NEWS IPC8 For general information regarding STN implementation of IPC 8  
NEWS X25 X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 12:54:14 ON 20 OCT 2006

=> file reg  
COST IN U.S. DOLLARS

SINCE FILE TOTAL  
ENTRY SESSION

Updated Search

11454322

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 12:54:21 ON 20 OCT 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 19 OCT 2006 HIGHEST RN 910855-26-4  
DICTIONARY FILE UPDATES: 19 OCT 2006 HIGHEST RN 910855-26-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> file hcaplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.44

0.65

FILE 'HCAPLUS' ENTERED AT 12:54:26 ON 20 OCT 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is  
held by the publishers listed in the PUBLISHER (PB) field (available  
for records published or updated in Chemical Abstracts after December  
26, 1996), unless otherwise indicated in the original publications.  
The CA Lexicon is the copyrighted intellectual property of the  
the American Chemical Society and is provided to assist you in searching  
databases on STN. Any dissemination, distribution, copying, or storing  
of this information, without the prior written consent of CAS, is  
strictly prohibited.

FILE COVERS 1907 - 20 Oct 2006 VOL 145 ISS 18  
FILE LAST UPDATED: 19 Oct 2006 (20061019/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate  
substance identification.

=> s ouabiain-induced () arrhythmia?

0 OUABIAIN

1555481 INDUCED

Updated Search

11454322

```

    13 INDUCEDS
1555486 INDUCED
      (INDUCED OR INDUCEDS)
    0 OUABIIN-INDUCED
      (OUABIIN(W) INDUCED)
    17054 ARRHYTHMIA?
L1      0 OUABIIN-INDUCED (W) ARRHYTHMIA?

=> s oubain-induced () arrhythmia?
    45 OUBAIN
1555481 INDUCED
    13 INDUCEDS
1555486 INDUCED
      (INDUCED OR INDUCEDS)
    0 OUBAIN-INDUCED
      (OUBAIN(W) INDUCED)
    17054 ARRHYTHMIA?
L2      0 OUBAIN-INDUCED (W) ARRHYTHMIA?

=> s na/ca () exchange () mechanism?
'CA' IS NOT A VALID FIELD CODE
    0 NA/CA
    564974 EXCHANGE
    17036 EXCHANGES
    573126 EXCHANGE
      (EXCHANGE OR EXCHANGES)
    1705900 MECHANISM?
L3      0 NA/CA (W) EXCHANGE (W) MECHANISM?

=> s sodium
    1065907 SODIUM
    36 SODIUMS
L4      1065916 SODIUM
      (SODIUM OR SODIUMS)

=> s calcium
    784962 CALCIUM
    37 CALCIUMS
L5      784965 CALCIUM
      (CALCIUM OR CALCIUMS)

=> s l4 () l5
L6      5981 L4 (W) L5

=> s l6 () exchange () mechanism?
    564974 EXCHANGE
    17036 EXCHANGES
    573126 EXCHANGE
      (EXCHANGE OR EXCHANGES)
    1705900 MECHANISM?
L7      26 L6 (W) EXCHANGE (W) MECHANISM?

=> s l7 and arrhythmia?
    17054 ARRHYTHMIA?
L8      0 L7 AND ARRHYTHMIA?

=> s l7 and review/dt
    1967450 REVIEW/DT
L9      3 L7 AND REVIEW/DT
```

Updated Search

11454322

=> d 19, ibib abs hitstr, 1-3

L9 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1998:153623 HCAPLUS

DOCUMENT NUMBER: 128:252366

TITLE: Cardiac sodium channels as targets for new inotropic agents

AUTHOR(S): Steinberg, Mitchell I.; Mccall, Eileen; Mest, Hans-Jurgen; Raap, Achim; Wright, Theresa

CORPORATE SOURCE: Lilly Research Laboratories, Indianapolis, IN, 46285, USA

SOURCE: Heart Failure Reviews (1998), 2(3), 173-193

CODEN: HFREFC; ISSN: 1382-4147

PUBLISHER: Kluwer Academic Publishers

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

AB A review with 191 refs. Congestive heart failure (CHF) is the most frequent cause of hospitalization in patients over 65. Hospitalized patients with severe CHF could benefit from new agents that directly support myocardial contractility and peripheral hemodynamics. The few classes of drugs available for short-term use (beta agonists, digoxin, and phosphodiesterase inhibitors) all act via cAMP and have significant limitations, including tolerance, tachyarrhythmias, and excessive vasodilation, especially in late-stage disease. Newer agents are in development

that increase contractility by novel mechanisms, including calcium sensitizers and ion channel modulators. Among the latter, sodium-channel modulators (e.g., DPI 201-106 and LY333612) interfere directly with inactivation of the rapid sodium channel. The authors review the structure and function of the human sodium channel and discuss the role of the sodium-calcium exchange mechanism in modulating the amount of calcium available for use in myocardial contraction. Sodium channel enhancers markedly increase contractility independent of cAMP in papillary muscle strips from patients with advanced CHF that are refractory to standard agents. Moreover, the unfavorable systolic and diastolic force-frequency relationships of isolated papillary muscle in advanced CHF are improved by some agents in this class. In ischemic CHF animal models, stroke volume and output are enhanced in the absence of pos. chronotropic or arrhythmogenic activity. Addnl. studies are suggested to help determine the ultimate role for these agents in the therapy of end-stage CHF.

REFERENCE COUNT: 191 THERE ARE 191 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1992:78650 HCAPLUS

DOCUMENT NUMBER: 116:78650

TITLE: Molecular aspects of sodium-calcium exchange

AUTHOR(S): Reeves, John P.

CORPORATE SOURCE: Roche Res. Cent., Roche Inst. Mol. Biol., Nutley, NJ, 07110, USA

SOURCE: Archives of Biochemistry and Biophysics (1992), 292(2), 329-34

CODEN: ABBIA4; ISSN: 0003-9861

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

AB A review with 44 refs. which focuses primarily upon recent biochem. and

Updated Search

11454322

mol. studies of the Na<sup>+</sup>/Ca<sup>2+</sup> exchange carrier and its reaction mechanism.

L9 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1984:417404 HCAPLUS

DOCUMENT NUMBER: 101:17404

TITLE: A possible physiological role of the sodium/  
calcium exchange mechanism  
of brown-fat mitochondria in the mediation of  
 $\alpha$ 1-adrenergic signals

AUTHOR(S): Nedergaard, Jan; Connolly, Examonn; Naanberg, Eewa;  
Mohell, Nina

CORPORATE SOURCE: Wenner-Gren Inst., Univ. Stockholm, Stockholm, S-113  
45, Swed.

SOURCE: Biochemical Society Transactions (1984), 12(3), 393-6  
CODEN: BCSTB5; ISSN: 0300-5127

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English


AB A review and discussion with 34 refs. on the Na<sup>+</sup>/Ca<sup>2+</sup> exchange (antiport)  
in mitochondria of brown adipose tissue and its role in the mediation of  
 $\alpha$ 1-adrenergic stimuli (noradrenaline [51-41-2]).

10541677

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Acetamide, N-[(3R,4S)-4-[[2-(4-ethoxy-3-methoxyphenyl)ethyl]amino]-3,4-dihydro-3-hydroxy-2,2-dimethyl-7-nitro-2H-1-benzopyran-6-yl]-, rel- (9CI)  
MF C24 H31 N3 O7


Relative stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Cyclopropanecarboxamide, N-[(3R,4S)-3,4-dihydro-3-hydroxy-2,2-dimethyl-7-nitro-4-[(phenylmethyl)amino]-2H-1-benzopyran-6-yl]-, rel- (9CI)  
MF C22 H25 N3 O5

Relative stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

Updated Search


10541677

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Phenol, 4-(2-aminoethyl)- (9CI)  
MF C8 H11 N O  
CI COM



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Benzeneethanamine, 2,4-dichloro- (9CI)  
MF C8 H9 Cl2 N  
CI COM



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Acetamide, N-[(3R,4S)-3,4-dihydro-3-hydroxy-2,2-dimethyl-7-nitro-4-[[2-(4-pyridinyl)ethyl]amino]-2H-1-benzopyran-6-yl]-, rel- (9CI)  
MF C20 H24 N4 O5

Relative stereochemistry.




Updated Search

10541677

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Cyclopropanecarboxamide, N-[(3R,4S)-3,4-dihydro-3-hydroxy-2,2-dimethyl-7-nitro-4-[(3-phenylpropyl)amino]-2H-1-benzopyran-6-yl]-, rel- (9CI)  
MF C24 H29 N3 O5

Relative stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Acetamide, N-(1a,7b-dihydro-2,2-dimethyl-5-nitro-2H-oxireno[c][1]benzopyran-6-yl)-2,2,2-trifluoro- (9CI)  
MF C13 H11 F3 N2 O5



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN [1,1'-Biphenyl]-4-ethanamine (9CI)  
MF C14 H15 N  
CI COM




Updated Search

10541677

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Acetamide, N-[(3R,4S)-4-[[2-(2-chlorophenyl)ethyl]amino]-3,4-dihydro-3-hydroxy-2,2-dimethyl-7-nitro-2H-1-benzopyran-6-yl]-, rel- (9CI)  
MF C21 H24 Cl N3 O5

Relative stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Propanamide, N-[(3R,4S)-4-[[2-(4-fluorophenyl)ethyl]amino]-3,4-dihydro-3-hydroxy-2,2-dimethyl-7-nitro-2H-1-benzopyran-6-yl]-2-methyl-, monohydrochloride, rel- (9CI)  
MF C23 H28 F N3 O5 . Cl H

Relative stereochemistry.


10541677



● HCl

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Acetamide, N-[(3R,4S)-4-[[2-(2-fluorophenyl)ethyl]amino]-3,4-dihydro-3-hydroxy-2,2-dimethyl-7-nitro-2H-1-benzopyran-6-yl]- (9CI)  
MF C21 H24 F N3 O5

Absolute stereochemistry. Rotation (-).



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Benzeneethanamine,  $\beta$ -phenyl- (9CI)  
MF C14 H15 N  
CI COM

$\text{Ph}_2\text{CH}-\text{CH}_2-\text{NH}_2$


Updated Search

10541677

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Acetamide, N-[(3R,4S)-4-[[2-(4-aminophenyl)ethyl]amino]-3,4-dihydro-3-hydroxy-2,2-dimethyl-7-nitro-2H-1-benzopyran-6-yl]-, rel- (9CI)  
MF C21 H26 N4 O5


Relative stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Propanamide, N-[(3R,4S)-3,4-dihydro-3-hydroxy-2,2-dimethyl-7-nitro-4-[(phenylmethyl)amino]-2H-1-benzopyran-6-yl]-2-methyl-, monohydrochloride, rel- (9CI)  
MF C22 H27 N3 O5 . Cl H

Relative stereochemistry.



● HCl


L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Formamide, N-[(3R,4S)-3,4-dihydro-3-hydroxy-2,2-dimethyl-7-nitro-4-[(2-phenylethyl)amino]-2H-1-benzopyran-6-yl]-, rel- (9CI)

Updated Search

10541677


MF C20 H23 N3 O5

Relative stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Benzeneethanamine, 3-fluoro- (9CI)  
MF C8 H10 F N  
CI COM



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Acetamide, N-[(1aR,7bR)-1a,7b-dihydro-2,2-dimethyl-5-nitro-2H-oxireno[c][1]benzopyran-6-yl]- (9CI)  
MF C13 H14 N2 O5

Absolute stereochemistry. Rotation (-).




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Acetamide, N-[(3R,4S)-4-[[2-(3,4-dichlorophenyl)ethyl]amino]-3,4-dihydro-3-hydroxy-2,2-dimethyl-7-nitro-2H-1-benzopyran-6-yl]-, rel- (9CI)  
MF C21 H23 Cl2 N3 O5

Updated Search

10541677


Relative stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Cyclopropanecarboxamide, N-[(3R,4S)-4-[[2-(3-chlorophenyl)ethyl]amino]-3,4-dihydro-3-hydroxy-2,2-dimethyl-7-nitro-2H-1-benzopyran-6-yl]-, rel- (9CI)  
MF C23 H26 Cl N3 O5

Relative stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 127 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN

Updated Search

10541677





IN 1H-Indole-3-ethanamine (9CI)  
MF C10 H12 N2  
CI COM



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

ALL ANSWERS HAVE BEEN SCANNED

Updated Search



chain nodes :

17 18 19 20 25 26 27 28 29 30 38

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

chain bonds :

6-9 19-20 25-26 27-28

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 11-13 12-16 13-14 14-15 15-16

exact/norm bonds :

6-9 7-8 7-12 8-9 9-10 10-11 11-12 11-13 12-16 19-20 25-26 27-28

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 13-14 14-15 15-16

isolated ring systems :

containing 1 : 7 :

G1:[\*1],[\*2],[\*3]

G2:[\*4],[\*5],[\*6],[\*7]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom 12:Atom  
13:Atom 14:Atom 15:Atom 16:Atom 17:CLASS 18:CLASS 19:CLASS 20:CLASS 25:CLASS 26:CLASS 27:CLASS  
28:CLASS 29:CLASS 30:CLASS 38:Atom 39:Atom

Generic attributes :

38:

Saturation : Unsaturated

Number of Carbon Atoms : less than 7

Number of Hetero Atoms : Exactly 1



Type of Ring System : Monocyclic

Element Count :

Node 38: Limited

C,C5

N,N1



chain nodes :

17 18 19 20 25 26 27 28 29 30

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 39 40 41 42 43 44

chain bonds :

6-9 19-20 25-26 27-28

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 11-13 12-16 13-14 14-15 15-16  
39-40 39-44 40-41 41-42 42-43 43-44

exact/norm bonds :

6-9 7-8 7-12 8-9 9-10 10-11 11-12 11-13 12-16 19-20 25-26 27-28

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 13-14 14-15 15-16 39-40 39-44 40-41 41-42 42-43 43-44

isolated ring systems :

containing 1 : 7 ;


G1:[\*1],[\*2],[\*3]

G2:[\*4],[\*5],[\*6],[\*7]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom 12:Atom  
13:Atom 14:Atom 15:Atom 16:Atom 17:CLASS 18:CLASS 19:CLASS 20:CLASS 25:CLASS 26:CLASS 27:CLASS  
28:CLASS

29:CLAS\$30:CLAS\$39:CLAS\$40:CLAS\$41:CLAS\$42:Atom 43:Atom 44:Atom 45:Atom



chain nodes :

17 18 19 20 25 26 27 28 29 30 45

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 39 40 41 42 43 44

chain bonds :

6-9 15-45 19-20 25-26 27-28

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 11-13 12-16 13-14 14-15 15-16  
39-40 39-44 40-41 41-42 42-43 43-44

exact/norm bonds :

6-9 7-8 7-12 8-9 9-10 10-11 15-45 19-20 25-26 27-28

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 11-12 11-13 12-16 13-14 14-15 15-16 39-40 39-44 40-41 41-42 42-43  
43-44

isolated ring systems :

containing 1 : 7 :


G1:[\*1],[\*2],[\*3]

G2:[\*4],[\*5],[\*6],[\*7]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom 12:Atom  
13:Atom

14:Atom 15:Atom 16:Atom 17:CLASS18:CLASS19:CLASS20:CLASS25:CLASS26:CLASS27:CLASS  
28:CLASS29:CLASS30:CLASS39:CLASS40:CLASS41:CLASS42:Atom 43:Atom 44:Atom 45:CLASS46:Atom



chain nodes :

17 18 19 20 25 26 27 28 29 30 45

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 39 40 41 42 43 44

chain bonds :

6-9 16-45 19-20 25-26 27-28

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 11-13 12-16 13-14 14-15 15-16  
39-40 39-44 40-41 41-42 42-43 43-44

exact/norm bonds :

6-9 7-8 7-12 8-9 9-10 10-11 16-45 19-20 25-26 27-28

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 11-12 11-13 12-16 13-14 14-15 15-16 39-40 39-44 40-41 41-42 42-43  
43-44

isolated ring systems :

containing 1 : 7 :






G1:[\*1],[\*2],[\*3]

G2:[\*4],[\*5],[\*6],[\*7]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom 12:Atom  
13:Atom

14:Atom 15:Atom 16:Atom 17:CLASS18:CLASS19:CLASS20:CLASS25:CLASS26:CLASS27:CLASS  
28:CLASS29:CLASS30:CLASS39:CLASS40:CLASS41:CLASS42:Atom 43:Atom 44:Atom 45:CLASS46:Atom



chain nodes :

17 18 19 20 25 26 27 28 29 30 45

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 39 40 41 42 43 44

chain bonds :

6-9 14-45 19-20 25-26 27-28

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 11-13 12-16 13-14 14-15 15-16  
39-40 39-44 40-41 41-42 42-43 43-44

exact/norm bonds :

6-9 7-8 7-12 8-9 9-10 10-11 14-45 19-20 25-26 27-28

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 11-12 11-13 12-16 13-14 14-15 15-16 39-40 39-44 40-41 41-42 42-43  
43-44

isolated ring systems :

containing 1 : 7 :

G1:[\*1],[\*2],[\*3]

G2:[\*4],[\*5],[\*6],[\*7]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom 12:Atom  
13:Atom

14:Atom 15:Atom 16:Atom 17:CLASS18:CLASS19:CLASS20:CLASS25:CLASS26:CLASS27:CLASS  
28:CLASS29:CLASS30:CLASS39:CLASS40:CLASS41:CLASS42:Atom 43:Atom 44:Atom 45:CLASS46:Atom

10541677

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal612bxr

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	FEB 27	New STN AnaVist pricing effective March 1, 2006
NEWS	4	MAY 10	CA/Capplus enhanced with 1900-1906 U.S. patent records
NEWS	5	MAY 11	KOREAPAT updates resume
NEWS	6	MAY 19	Derwent World Patents Index to be reloaded and enhanced
NEWS	7	MAY 30	IPC 8 Rolled-up Core codes added to CA/Capplus and USPATFULL/USPAT2
NEWS	8	MAY 30	The F-Term thesaurus is now available in CA/Capplus
NEWS	9	JUN 02	The first reclassification of IPC codes now complete in INPADOC
NEWS	10	JUN 26	TULSA/TULSA2 reloaded and enhanced with new search and and display fields
NEWS	11	JUN 28	Price changes in full-text patent databases EPFULL and PCTFULL
NEWS	12	JUL 11	CHEMSAFE reloaded and enhanced
NEWS	13	JUL 14	FSTA enhanced with Japanese patents
NEWS	14	JUL 19	Coverage of Research Disclosure reinstated in DWPI
NEWS	15	AUG 09	INSPEC enhanced with 1898-1968 archive
NEWS	16	AUG 28	ADISCTI Reloaded and Enhanced
NEWS	17	AUG 30	CA(SM)/Capplus(SM) Austrian patent law changes
NEWS	18	SEP 11	CA/Capplus enhanced with more pre-1907 records
NEWS	19	SEP 21	CA/Capplus fields enhanced with simultaneous left and right truncation
NEWS	20	SEP 25	CA(SM)/Capplus(SM) display of CA Lexicon enhanced
NEWS	21	SEP 25	CAS REGISTRY(SM) no longer includes Concord 3D coordinates
NEWS	22	SEP 25	CAS REGISTRY(SM) updated with amino acid codes for pyrrolysine
NEWS	23	SEP 28	CEABA-VTB classification code fields reloaded with new classification scheme
NEWS EXPRESS	JUNE 30 CURRENT WINDOWS VERSION IS V8.01b, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.		
NEWS HOURS	STN Operating Hours Plus Help Desk Availability		
NEWS LOGIN	Welcome Banner and News Items		
NEWS IPC8	For general information regarding STN implementation of IPC 8		
NEWS X25	X.25 communication option no longer available		

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific

Updated Search

10541677

research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 11:50:08 ON 16 OCT 2006

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 11:50:14 ON 16 OCT 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 15 OCT 2006 HIGHEST RN 910448-76-9

DICTIONARY FILE UPDATES: 15 OCT 2006 HIGHEST RN 910448-76-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Documents and Settings\brobinson1\My Documents\stnweb\Queries\45454ff.str

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 11:55:53 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 604562 TO ITERATE

0.3% PROCESSED 2000 ITERATIONS  
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

0 ANSWERS

Updated Search

10541677

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*INCOMPLETE\*\*  
BATCH \*\*INCOMPLETE\*\*  
PROJECTED ITERATIONS: 12047886 TO 12134594  
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=>

Uploading C:\Documents and Settings\brobinson1\My Documents\stnweb\Queries\556jt.str

L3 STRUCTURE UPLOADED

=> s 13

SAMPLE SEARCH INITIATED 11:57:50 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 63222 TO ITERATE

3.2% PROCESSED 2000 ITERATIONS 0 ANSWERS  
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*INCOMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 1249462 TO 1279418  
PROJECTED ANSWERS: 0 TO 0

L4 0 SEA SSS SAM L3

=>

Uploading C:\Documents and Settings\brobinson1\My Documents\stnweb\Queries\56ee56.str

L5 STRUCTURE UPLOADED

=> d 15

L5 HAS NO ANSWERS

L5 STR

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

Structure attributes must be viewed using STN Express query preparation.

=> s 15

SAMPLE SEARCH INITIATED 11:59:26 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 43944 TO ITERATE

4.6% PROCESSED 2000 ITERATIONS 0 ANSWERS  
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 866365 TO 891395  
PROJECTED ANSWERS: 0 TO 0

L6 0 SEA SSS SAM L5

Updated Search

10541677

=> s l5 full

THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 166.50 U.S. DOLLARS  
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y  
FULL SEARCH INITIATED 11:59:30 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 879031 TO ITERATE

100.0% PROCESSED 879031 ITERATIONS  
SEARCH TIME: 00.00.05

37 ANSWERS

L7 37 SEA SSS FUL L5

=> file hcaplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

173.54

173.75

FILE 'HCAPLUS' ENTERED AT 11:59:39 ON 16 OCT 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 16 Oct 2006 VOL 145 ISS 17  
FILE LAST UPDATED: 15 Oct 2006 (20061015/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l7

L8 2 L7

=> d l8,ibib abs hitstr, 1-2

L8 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:606465 HCAPLUS

DOCUMENT NUMBER: 141:157037

TITLE: Preparation of pyridine derivatives useful for inhibiting sodium/calcium exchange system

INVENTOR(S): Otsomaa, Leena; Koskelainen, Tuula; Karjalainen, Arto; Rasku, Sirpa; Pollesello, Piero; Levijoki, Jouko

PATENT ASSIGNEE(S): Orion Corporation, Finland

SOURCE: PCT Int. Appl., 108 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

Updated Search

10541677

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004063191	A1	20040729	WO 2004-FI11	20040109
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ				
AU 2004203943	A1	20040729	AU 2004-203943	20040109
CA 2512184	AA	20040729	CA 2004-2512184	20040109
EP 1583759	A1	20051012	EP 2004-701023	20040109
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2004006669	A	20051220	BR 2004-6669	20040109
CN 1745078	A	20060308	CN 2004-80003357	20040109
JP 2006516271	T2	20060629	JP 2006-500151	20040109
NO 2005003730	A	20051007	NO 2005-3730	20050803
PRIORITY APPLN. INFO.:			FI 2003-30	A 20030109
			WO 2004-FI11	W 20040109
OTHER SOURCE(S):		MARPAT 141:157037		
GI				



AB Title compds. I [X = O, CH<sub>2</sub>, CO; Z = divalent alkyl, bond; Y = CH<sub>2</sub>, CO, divalent alkyl, etc.; R<sub>2</sub>-3 = H, alkyl, alkoxy, etc.; R<sub>1</sub> = H, CN, halo, etc. with provisos] are prepared For instance, II is prepared from 2-chloro-5-nitropyridine and 6-hydroxyflavone (DMF, 120°, 30 min). I are potent inhibitors of Na<sup>+</sup>/Ca<sup>2+</sup> exchange mechanism.

IT 728935-24-8P, 6-((5-Nitropyridin-2-yl)oxy)-2-[4-((5-nitropyridin-2-yl)oxy)phenyl]chroman-4-ol


Updated Search

10541677

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(preparation of pyridine derivs. useful for inhibiting sodium/calcium exchange system)

RN 728935-24-8 HCAPLUS

CN 2H-1-Benzopyran-4-ol, 3,4-dihydro-6-[(5-nitro-2-pyridinyl)oxy]-2-[4-[(5-nitro-2-pyridinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)




IT 728935-22-6P, 6-((5-Nitropyridin-2-yl)oxy)-2-[3-((5-nitropyridin-2-yl)oxy)phenyl]chroman-4-ol 728935-37-3P, 6-((5-Aminopyridin-2-yl)oxy)-2-[3-((5-aminopyridin-2-yl)oxy)phenyl]chroman-4-ol dihydrochloride 728937-09-5P, 6-[[5-[(Methanesulfonyl)amino]pyridin-6-yl]oxy]-2-[3-[[5-[(methanesulfonyl)amino]pyridin-6-yl]oxy]phenyl]chroman-4-ol  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyridine derivs. useful for inhibiting sodium/calcium exchange system)


RN 728935-22-6 HCAPLUS

CN 2H-1-Benzopyran-4-ol, 3,4-dihydro-6-[(5-nitro-2-pyridinyl)oxy]-2-[3-[(5-nitro-2-pyridinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 728935-37-3 HCAPLUS

CN 2H-1-Benzopyran-4-ol, 6-[(5-amino-2-pyridinyl)oxy]-2-[3-[(5-amino-2-pyridinyl)oxy]phenyl]-3,4-dihydro-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

Updated Search

10541677

RN 728937-09-5 HCAPLUS

CN Methanesulfonamide, N-[2-[3-[3,4-dihydro-4-hydroxy-6-[[3-[(methylsulfonyl)amino]-2-pyridinyl]oxy]-2H-1-benzopyran-2-yl]phenoxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)




IT 488847-51-4P, 6-(5-Nitropyridin-2-yloxy)-2-phenylchroman-4-one  
488848-38-0P, 2-(2,3-Dihydro-2-phenylbenzo[1,4]dioxin-6-yloxy)-5-nitropyridine 488849-22-5P, 6-(5-Aminopyridin-2-yloxy)-2-phenylchroman-4-one 488849-71-4P, 2-[3-(3-Fluorophenyl)chroman-7-yloxy]-5-nitropyridine 488849-76-9P, 2-[3-(Phenyl)chroman-7-yloxy]-5-nitropyridine 488849-79-2P, 5-Nitro-2-(2-phenyl-2,3-dihydrobenzo[1,4]oxathiin-6-yloxy)pyridine 728934-75-6P, 6-(2-Phenyl-2,3-dihydrobenzo[1,4]oxathiin-6-yloxy)pyridin-3-ylamine hydrochloride

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of pyridine derivs. useful for inhibiting sodium/calcium exchange system)


RN 488847-51-4 HCAPLUS

CN 4H-1-Benzopyran-4-one, 2,3-dihydro-6-[(5-nitro-2-pyridinyl)oxy]-2-phenyl- (9CI) (CA INDEX NAME)



RN 488848-38-0 HCAPLUS

CN Pyridine, 2-[(2,3-dihydro-2-phenyl-1,4-benzodioxin-6-yl)oxy]-5-nitro- (9CI) (CA INDEX NAME)




Updated Search

10541677


RN 488849-22-5 HCAPLUS

CN 4H-1-Benzopyran-4-one, 6-[(5-amino-2-pyridinyl)oxy]-2,3-dihydro-2-phenyl-  
(9CI) (CA INDEX NAME)




RN 488849-71-4 HCAPLUS

CN Pyridine, 2-[[3-(3-fluorophenyl)-3,4-dihydro-2H-1-benzopyran-7-yl]oxy]-5-nitro-  
(9CI) (CA INDEX NAME)




RN 488849-76-9 HCAPLUS

CN Pyridine, 2-[[3-(3,4-dihydro-3-phenyl-2H-1-benzopyran-7-yl)oxy]-5-nitro-  
(9CI) (CA INDEX NAME)



RN 488849-79-2 HCAPLUS

CN Pyridine, 2-[(2,3-dihydro-2-phenyl-1,4-benzoxathiin-6-yl)oxy]-5-nitro-  
(9CI) (CA INDEX NAME)




RN 728934-75-6 HCAPLUS

CN 3-Pyridinamine, 6-[(2,3-dihydro-2-phenyl-1,4-benzoxathiin-6-yl)oxy]-,  
monohydrochloride (9CI) (CA INDEX NAME)

Updated Search

10541677



● HCl

L8 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:58077 HCAPLUS

DOCUMENT NUMBER: 138:122550

TITLE: Preparation of phenyl chromans, benzo[1,4]dioxins, indans, and naphthalenes as potent inhibitors of Na<sup>+</sup>/Ca<sup>2+</sup> exchange mechanism for treatment of arrhythmias

INVENTOR(S): Koskelainen, Tuula; Otsomaa, Leena; Karjalainen, Arto; Kotovuori, Pekka; Tenhunen, Jukka; Rasku, Sirpa; Nore, Pentti; Tiainen, Eija; Toermaekangas, Olli

PATENT ASSIGNEE(S): Orion Corporation, Finland

SOURCE: PCT Int. Appl., 98 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003006452	A1	20030123	WO 2002-FI621	20020710
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2452918	AA	20030123	CA 2002-2452918	20020710
EP 1412343	A1	20040428	EP 2002-755036	20020710
EP 1412343	B1	20060830		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK			
BR 2002011070	A	20040615	BR 2002-11070	20020710
CN 1525966	A	20040901	CN 2002-813863	20020710
JP 2005504738	T2	20050217	JP 2003-512224	20020710
NZ 530490	A	20051223	NZ 2002-530490	20020710
AT 338038	E	20060915	AT 2002-755036	20020710
NO 2003005821	A	20040224	NO 2003-5821	20031223
ZA 2004000145	A	20050408	ZA 2004-145	20040108
US 2004235905	A1	20041125	US 2004-482396	20040608



PRIORITY APPLN. INFO.:

FI 2001-1507 A 20010710  
WO 2002-FI621 W 20020710

OTHER SOURCE(S): MARPAT 138:122550

Updated Search

GI



AB Title therapeutically active compds. I [wherein X = O, CH<sub>2</sub>, or CO; Z = CHR<sub>9</sub> or bond; Y = CH<sub>2</sub>, CO, CHOR<sub>10</sub>, CHNR<sub>11</sub>R<sub>12</sub>, O, S, SO, or SO<sub>2</sub>, provided that when Z = a bond, Y ≠ CO; the dashed line = optional double bond when Z = CR<sub>9</sub> and Y = CH, COR<sub>10</sub>, or CNR<sub>11</sub>R<sub>12</sub>; R<sub>1</sub> = (CH<sub>2</sub>)<sub>n</sub>NR<sub>4</sub>R<sub>7</sub> or dihydroimidazolylmethyl or (un)substituted 2-aminophenyl or 2-pyridyl; n = 1-4; R<sub>2</sub> and R<sub>3</sub> = independently H, alkyl, alkoxy, NO<sub>2</sub>, halo, CF<sub>3</sub>, OH, NHR<sub>8</sub>, or CO<sub>2</sub>H; R<sub>4</sub> and R<sub>7</sub> = independently H or (hydroxy)alkyl; R<sub>8</sub> = H or acyl; R<sub>9</sub> = H or alkyl; R<sub>10</sub> = H, alkylsulfonyl, or acyl; R<sub>11</sub> and R<sub>12</sub> = independently H, alkyl, or acyl; and pharmaceutically acceptable salts and esters thereof] were prepared as inhibitors of Na<sup>+</sup>/Ca<sup>2+</sup> exchange mechanism in cells. For example, 6-hydroxyflavanone was reduced to 2-phenylchroman-6-ol and coupled with 2-chloro-5-nitropyridine. Reduction to the amine using glacial acetic acid and Zn powder followed by acetylation gave 5-(acetylamino)-2-(2-phenylchroman-6-yloxy)pyridine (II). The latter delayed the appearance (38 ± 7.5 min vs. vehicle) and decreased the amplitude (74 ± 16 mg vs. vehicle) of ouabain-induced arrhythmias in guinea-pig papillary muscles at a concentration of 30 μM. Thus, I are useful for the treatment of arrhythmias.

IT 488847-51-4P, 6-[(5-Nitropyridin-2-yl)oxy]-2-phenylchroman-4-one  
 488847-55-8P, 6-[(5-Nitropyridin-2-yl)oxy]-2-phenylchroman-4-ol  
 488849-79-2P, 5-Nitro-2-[(2-phenyl-2,3-dihydrobenzo[1,4]oxathiin-6-yl)oxy]pyridine 488849-99-6P, 2-(4-Methoxyphenyl)-6-[(5-nitropyridin-2-yl)oxy]chroman-4-ol 488850-00-6P  
 488850-02-8P, 2-(2-Methoxyphenyl)-6-[(5-nitropyridin-2-yl)oxy]chroman-4-ol 488850-11-9P, 2-(3-Methoxyphenyl)-6-[(5-nitropyridin-2-yl)oxy]chroman-4-ol


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(antiarrhythmic; preparation of Ph chromans, benzo[1,4]dioxins, indans, and naphthalenes as potent inhibitors of Na<sup>+</sup>/Ca<sup>2+</sup> exchange mechanism for treatment of arrhythmias)

RN 488847-51-4 HCAPLUS


CN 4H-1-Benzopyran-4-one, 2,3-dihydro-6-[(5-nitro-2-pyridinyl)oxy]-2-phenyl-  
 (9CI) (CA INDEX NAME)

10541677




RN 488847-55-8 HCAPLUS

CN 2H-1-Benzopyran-4-ol, 3,4-dihydro-6-[(5-nitro-2-pyridinyl)oxy]-2-phenyl-  
(9CI) (CA INDEX NAME)




RN 488849-79-2 HCAPLUS

CN Pyridine, 2-[(2,3-dihydro-2-phenyl-1,4-benzoxathiin-6-yl)oxy]-5-nitro-  
(9CI) (CA INDEX NAME)



RN 488849-99-6 HCAPLUS

CN 2H-1-Benzopyran-4-ol, 3,4-dihydro-2-(4-methoxyphenyl)-6-[(5-nitro-2-pyridinyl)oxy]- (9CI) (CA INDEX NAME)




RN 488850-00-6 HCAPLUS

CN 2H-1-Benzopyran-4-ol, 6-[(5-amino-2-pyridinyl)oxy]-3,4-dihydro-2-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)


Updated Search

10541677




RN 488850-02-8 HCAPLUS

CN 2H-1-Benzopyran-4-ol, 3,4-dihydro-2-(2-methoxyphenyl)-6-[(5-nitro-2-pyridinyl)oxy]- (9CI) (CA INDEX NAME)



RN 488850-11-9 HCAPLUS

CN 2H-1-Benzopyran-4-ol, 3,4-dihydro-2-(3-methoxyphenyl)-6-[(5-nitro-2-pyridinyl)oxy]- (9CI) (CA INDEX NAME)



IT 488848-38-0P, 2-[(2,3-Dihydro-2-phenylbenzo[1,4]dioxin-6-yl)oxy]-5-nitropyridine 488848-51-7P, 2-[(2,3-Dihydro-2-phenylbenzo[1,4]dioxin-6-yl)oxy]-3-nitropyridine 488848-53-9P, 2-[(2,3-Dihydro-2-phenylbenzo[1,4]dioxin-6-yl)oxy]-5-trifluoromethylpyridine 488849-22-5P, 6-[(5-Aminopyridin-2-yl)oxy]-2-phenylchroman-4-one 488849-23-6P, Acetic acid 6-[(5-nitropyridin-2-yl)oxy]-2-phenylchroman-4-yl ester 488849-27-0P, 2-(3-Bromophenyl)-6-[(5-nitropyridin-2-yl)oxy]chroman-4-ol 488849-28-1P, 2-(2-Fluorophenyl)-6-[(5-nitropyridin-2-yl)oxy]chroman-4-ol 488849-29-2P, 2-(2,5-Difluorophenyl)-6-[(5-nitropyridin-2-yl)oxy]chroman-4-ol 488849-30-5P, 2-(3-Fluorophenyl)-6-[(5-nitropyridin-2-yl)oxy]chroman-4-ol 488849-40-7P, 2-(4-Chlorophenyl)-6-[(5-nitropyridin-2-yl)oxy]chroman-4-ol 488849-49-6P, 2-(2,4-Difluorophenyl)-6-[(5-nitropyridin-2-yl)oxy]chroman-4-ol 488849-54-3P, 2-(2-Chlorophenyl)-6-[(5-nitropyridin-2-yl)oxy]chroman-4-ol 488849-65-6P, 2-(2,6-Difluorophenyl)-6-[(5-nitropyridin-2-yl)oxy]chroman-4-ol 488849-68-9P, 6-[(5-Nitropyridin-2-yl)oxy]-2-(2-trifluoromethylphenyl)chroman-4-ol 488849-71-4P, 2-[[3-(3-Fluorophenyl)chroman-7-yl]oxy]-5-

Updated Search


nitropyridine 488849-76-9P, 5-Nitro-2-[(3-phenylchroman-7-yl)oxy]pyridine 488849-82-7P, 5-Nitro-2-[(4-oxo-2-phenyl-3,4-dihydrobenzo[1,4]oxathiin-6-yl)oxy]pyridine 488849-83-8P, 2-[(4,4-Dioxo-2-phenyl-3,4-dihydrobenzo[1,4]oxathiin-6-yl)oxy]-5-nitropyridine 488850-01-7P, N-[6-[[4-Hydroxy-2-(4-methoxyphenyl)chroman-6-yl]oxy]pyridin-3-yl]acetamide 488850-04-0P, 6-[(5-Aminopyridin-2-yl)oxy]-2-(2-methoxyphenyl)chroman-4-ol 488850-12-0P, 6-[(5-Aminopyridin-2-yl)oxy]-2-(3-methoxyphenyl)chroman-4-ol 488850-13-1P, [6-[(2-Phenyl-2,3-dihydrobenzo[1,4]oxathiin-6-yl)oxy]pyridin-3-yl]amine dihydrochloride 488850-14-2P, N-[6-[(2-Phenyl-2,3-dihydrobenzo[1,4]oxathiin-6-yl)oxy]pyridin-3-yl]acetamide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(antiarrhythmic; preparation of Ph chromans, benzo[1,4]dioxins, indans, and naphthalenes as potent inhibitors of Na<sup>+</sup>/Ca<sup>2+</sup> exchange mechanism for treatment of arrhythmias)


RN 488848-38-0 HCAPLUS

CN Pyridine, 2-[(2,3-dihydro-2-phenyl-1,4-benzodioxin-6-yl)oxy]-5-nitro-(9CI) (CA INDEX NAME)




RN 488848-51-7 HCAPLUS

CN Pyridine, 2-[(2,3-dihydro-2-phenyl-1,4-benzodioxin-6-yl)oxy]-3-nitro-(9CI) (CA INDEX NAME)



RN 488848-53-9 HCAPLUS

CN Pyridine, 2-[(2,3-dihydro-2-phenyl-1,4-benzodioxin-6-yl)oxy]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 488849-22-5 HCAPLUS

CN 4H-1-Benzopyran-4-one, 6-[(5-amino-2-pyridinyl)oxy]-2,3-dihydro-2-phenyl-


10541677

(9CI) (CA INDEX NAME)




RN 488849-23-6 HCAPLUS

CN 2H-1-Benzopyran-4-ol, 3,4-dihydro-6-[(5-nitro-2-pyridinyl)oxy]-2-phenyl-, acetate (ester) (9CI) (CA INDEX NAME)




RN 488849-27-0 HCAPLUS

CN 2H-1-Benzopyran-4-ol, 2-(3-bromophenyl)-3,4-dihydro-6-[(5-nitro-2-pyridinyl)oxy]- (9CI) (CA INDEX NAME)



RN 488849-28-1 HCAPLUS

CN 2H-1-Benzopyran-4-ol, 2-(2-fluorophenyl)-3,4-dihydro-6-[(5-nitro-2-pyridinyl)oxy]- (9CI) (CA INDEX NAME)




RN 488849-29-2 HCAPLUS

CN 2H-1-Benzopyran-4-ol, 2-(2,5-difluorophenyl)-3,4-dihydro-6-[(5-nitro-2-pyridinyl)oxy]- (9CI) (CA INDEX NAME)


Updated Search

10541677




RN 488849-30-5 HCAPLUS

CN 2H-1-Benzopyran-4-ol, 2-(3-fluorophenyl)-3,4-dihydro-6-[(5-nitro-2-pyridinyl)oxy]- (9CI) (CA INDEX NAME)




RN 488849-40-7 HCAPLUS

CN 2H-1-Benzopyran-4-ol, 2-(4-chlorophenyl)-3,4-dihydro-6-[(5-nitro-2-pyridinyl)oxy]- (9CI) (CA INDEX NAME)



RN 488849-49-6 HCAPLUS

CN 2H-1-Benzopyran-4-ol, 2-(2,4-difluorophenyl)-3,4-dihydro-6-[(5-nitro-2-pyridinyl)oxy]- (9CI) (CA INDEX NAME)




RN 488849-54-3 HCAPLUS


CN 2H-1-Benzopyran-4-ol, 2-(2-chlorophenyl)-3,4-dihydro-6-[(5-nitro-2-pyridinyl)oxy]- (9CI) (CA INDEX NAME)

Updated Search


10541677




RN 488849-65-6 HCAPLUS  
CN 2H-1-Benzopyran-4-ol, 2-(2,6-difluorophenyl)-3,4-dihydro-6-[(5-nitro-2-pyridinyl)oxy]- (9CI) (CA INDEX NAME)



RN 488849-68-9 HCAPLUS  
CN 2H-1-Benzopyran-4-ol, 3,4-dihydro-6-[(5-nitro-2-pyridinyl)oxy]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 488849-71-4 HCAPLUS  
CN Pyridine, 2-[[3-(3-fluorophenyl)-3,4-dihydro-2H-1-benzopyran-7-yl]oxy]-5-nitro- (9CI) (CA INDEX NAME)



RN 488849-76-9 HCAPLUS  
CN Pyridine, 2-[[3-(3-fluorophenyl)-3,4-dihydro-2H-1-benzopyran-7-yl]oxy]-5-nitro- (9CI) (CA INDEX NAME)


Updated Search

10541677




RN 488849-82-7 HCAPLUS

CN Pyridine, 2-[(2,3-dihydro-4-oxido-2-phenyl-1,4-benzoxathiin-6-yl)oxy]-5-nitro- (9CI) (CA INDEX NAME)




RN 488849-83-8 HCAPLUS

CN Pyridine, 2-[(2,3-dihydro-4,4-dioxido-2-phenyl-1,4-benzoxathiin-6-yl)oxy]-5-nitro- (9CI) (CA INDEX NAME)



RN 488850-01-7 HCAPLUS

CN Acetamide, N-[6-[[3,4-dihydro-4-hydroxy-2-(4-methoxyphenyl)-2H-1-benzopyran-6-yl]oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 488850-04-0 HCAPLUS

CN 2H-1-Benzopyran-4-ol, 6-[(5-amino-2-pyridinyl)oxy]-3,4-dihydro-2-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)


Updated Search

10541677




RN 488850-12-0 HCAPLUS

CN 2H-1-Benzopyran-4-ol, 6-[(5-amino-2-pyridinyl)oxy]-3,4-dihydro-2-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 488850-13-1 HCAPLUS


CN 3-Pyridinamine, 6-[(2,3-dihydro-2-phenyl-1,4-benzoxathiin-6-yl)oxy]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 488850-14-2 HCAPLUS

CN Acetamide, N-[6-[(2,3-dihydro-2-phenyl-1,4-benzoxathiin-6-yl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)



IT 488850-15-3, [6-[(2-Phenyl-2,3-dihydrobenzo[1,4]oxathiin-6-yl)oxy]pyridin-3-yl]amine

RL: RCT (Reactant); RACT (Reactant or reagent)  
(preparation of Ph chromans, benzo[1,4]dioxins, indans, and naphthalenes as potent inhibitors of Na<sup>+</sup>/Ca<sup>2+</sup> exchange mechanism for treatment of arrhythmias)


RN 488850-15-3 HCAPLUS

CN 3-Pyridinamine, 6-[(2,3-dihydro-2-phenyl-1,4-benzoxathiin-6-yl)oxy]- (9CI)

Updated Search

10541677

(CA INDEX NAME)



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file caold  
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
12.75	186.50

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-1.50	-1.50

CA SUBSCRIBER PRICE

FILE 'CAOLD' ENTERED AT 11:59:59 ON 16 OCT 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966  
FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=> d his

(FILE 'HOME' ENTERED AT 11:50:08 ON 16 OCT 2006)

FILE 'REGISTRY' ENTERED AT 11:50:14 ON 16 OCT 2006

L1	STRUCTURE UPLOADED
L2	0 S L1
L3	STRUCTURE UPLOADED
L4	0 S L3
L5	STRUCTURE UPLOADED
L6	0 S L5
L7	37 S L5 FULL

FILE 'HCAPLUS' ENTERED AT 11:59:39 ON 16 OCT 2006

L8	2 S L7
----	--------

Updated Search

10541677

FILE 'CAOLD' ENTERED AT 11:59:59 ON 16 OCT 2006

=> s 17

L9 0 L7

=> file reg

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.44	186.94

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
0.00	-1.50

CA SUBSCRIBER PRICE

FILE 'REGISTRY' ENTERED AT 12:00:07 ON 16 OCT 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 15 OCT 2006 HIGHEST RN 910448-76-9

DICTIONARY FILE UPDATES: 15 OCT 2006 HIGHEST RN 910448-76-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Documents and Settings\brobinson1\My Documents\stnweb\Queries\3434tt.str

L10 STRUCTURE UPLOADED

=> d 110

L10 HAS NO ANSWERS

L10 STR

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

Structure attributes must be viewed using STN Express query preparation.

=> s 110

SAMPLE SEARCH INITIATED 12:01:18 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 43944 TO ITERATE

4.6% PROCESSED

2000 ITERATIONS

0 ANSWERS

Updated Search

10541677

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 866365 TO 891395  
PROJECTED ANSWERS: 0 TO 0

L11 0 SEA SSS SAM L10

=> s l10 full

THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 166.50 U.S. DOLLARS  
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y  
FULL SEARCH INITIATED 12:01:23 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 879031 TO ITERATE

100.0% PROCESSED 879031 ITERATIONS 0 ANSWERS  
SEARCH TIME: 00.00.04

L12 0 SEA SSS FUL L10

=>

Uploading C:\Documents and Settings\brobinson1\My Documents\stnweb\Queries\rui4.str

L13 STRUCTURE UPLOADED

=> d l13

L13 HAS NO ANSWERS  
L13 STR

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

Structure attributes must be viewed using STN Express query preparation.

=> s l13

SAMPLE SEARCH INITIATED 12:02:34 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 43944 TO ITERATE

4.6% PROCESSED 2000 ITERATIONS 0 ANSWERS  
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 866365 TO 891395  
PROJECTED ANSWERS: 0 TO 0

L14 0 SEA SSS SAM L13

=> s l13 full

THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 166.50 U.S. DOLLARS  
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y  
FULL SEARCH INITIATED 12:02:38 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 879031 TO ITERATE

100.0% PROCESSED 879031 ITERATIONS 1 ANSWERS  
SEARCH TIME: 00.00.04

Updated Search

10541677

L15 1 SEA SSS FUL L13

=> file hcaplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

334.76

521.70

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

0.00

-1.50

FILE 'HCAPLUS' ENTERED AT 12:02:46 ON 16 OCT 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 16 Oct 2006 VOL 145 ISS 17

FILE LAST UPDATED: 15 Oct 2006 (20061015/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l15

L16 2 L15

=> d his

(FILE 'HOME' ENTERED AT 11:50:08 ON 16 OCT 2006)

FILE 'REGISTRY' ENTERED AT 11:50:14 ON 16 OCT 2006

L1 STRUCTURE UPLOADED

L2 0 S L1

L3 STRUCTURE UPLOADED

L4 0 S L3

L5 STRUCTURE UPLOADED

L6 0 S L5

L7 37 S L5 FULL

FILE 'HCAPLUS' ENTERED AT 11:59:39 ON 16 OCT 2006

L8 2 S L7

FILE 'CAOLD' ENTERED AT 11:59:59 ON 16 OCT 2006

L9 0 S L7

FILE 'REGISTRY' ENTERED AT 12:00:07 ON 16 OCT 2006

L10 STRUCTURE UPLOADED

Updated Search

10541677

L11 0 S L10  
L12 0 S L10 FULL  
L13 STRUCTURE UPLOADED  
L14 0 S L13  
L15 1 S L13 FULL

FILE 'HCAPLUS' ENTERED AT 12:02:46 ON 16 OCT 2006  
L16 2 S L15

=> s l16 not l8  
L17 0 L16 NOT L8

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	2.53	524.23
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-1.50

FILE 'REGISTRY' ENTERED AT 12:02:59 ON 16 OCT 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 15 OCT 2006 HIGHEST RN 910448-76-9  
DICTIONARY FILE UPDATES: 15 OCT 2006 HIGHEST RN 910448-76-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>  
Uploading C:\Documents and Settings\brobinson1\My Documents\stnweb\Queries\4ii545.str

L18 STRUCTURE UPLOADED

=> s l18  
SAMPLE SEARCH INITIATED 12:14:53 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 43944 TO ITERATE

4.6% PROCESSED 2000 ITERATIONS 0 ANSWERS  
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
SEARCH TIME: 00.00.01

Updated Search

10541677

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 866365 TO 891395  
PROJECTED ANSWERS: 0 TO 0

L19 0 SEA SSS SAM L18

=> s l18 full

THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 166.50 U.S. DOLLARS  
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y  
FULL SEARCH INITIATED 12:14:57 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 879031 TO ITERATE

100.0% PROCESSED 879031 ITERATIONS 0 ANSWERS  
SEARCH TIME: 00.00.04

L20 0 SEA SSS FUL L18

=> file hcaplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	175.30	699.53
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-1.50

FILE 'HCAPLUS' ENTERED AT 12:15:04 ON 16 OCT 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 16 Oct 2006 VOL 145 ISS 17  
FILE LAST UPDATED: 15 Oct 2006 (20061015/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s otsomaa, l?/au and koskelainen, t?/au and karjalainen, a?/au and rasku, s?/au and pollesello, p?/au and levijoki, j?/au  
5 OTSOMAA, L?/AU  
2 KOSKELAINEN, T?/AU  
140 KARJALAINEN, A?/AU  
17 RASKU, S?/AU  
69 POLLESELLO, P?/AU

Updated Search

10541677

21 LEVIJOKI, J?/AU  
L21 1 OTSOMAA, L?/AU AND KOSKELAINEN, T?/AU AND KARJALAINEN, A?/AU  
AND RASKU, S?/AU AND POLLESELLO, P?/AU AND LEVIJOKI, J?/AU

=> d l21, ibib abs hitstr, 1

L21 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:606465 HCAPLUS

DOCUMENT NUMBER: 141:157037

TITLE: Preparation of pyridine derivatives useful for  
inhibiting sodium/calcium exchange system

INVENTOR(S): Otsomaa, Leena; Koskelainen, Tuula  
; Karjalainen, Arto; Rasku, Sirpa;  
Pollesello, Piero; Levijoki, Jouko

PATENT ASSIGNEE(S): Orion Corporation, Finland

SOURCE: PCT Int. Appl., 108 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent



LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004063191	A1	20040729	WO 2004-FI11	20040109
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ				
AU 2004203943	A1	20040729	AU 2004-203943	20040109
CA 2512184	AA	20040729	CA 2004-2512184	20040109
EP 1583759	A1	20051012	EP 2004-701023	20040109
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2004006669	A	20051220	BR 2004-6669	20040109
CN 1745078	A	20060308	CN 2004-80003357	20040109
JP 2006516271	T2	20060629	JP 2006-500151	20040109
NO 2005003730	A	20051007	NO 2005-3730	20050803
PRIORITY APPLN. INFO.:			FI 2003-30	A 20030109
			WO 2004-FI11	W 20040109
OTHER SOURCE(S):		MARPAT 141:157037		
GI				

10541677



AB Title compds. I [X = O, CH<sub>2</sub>, CO; Z = divalent alkyl, bond; Y = CH<sub>2</sub>, CO, divalent alkyl, etc.; R<sub>2</sub>-3 = H, alkyl, alkoxy, etc.; R<sub>1</sub> = H, CN, halo, etc. with provisos] are prepared For instance, II is prepared from 2-chloro-5-nitropyridine and 6-hydroxyflavone (DMF, 120°, 30 min). I are potent inhibitors of Na<sup>+</sup>/Ca<sup>2+</sup> exchange mechanism.